Novel compound and its preparation method and use
Patent Information
- Application Number
- CN202180007965.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-12-14
- Filing Date
- 2021-01-15
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-01-15
AI Technical Summary
然而,尽管有报道指出Pin1可帮助治疗大脑中的阿尔茨海默病,但是有报道指出其在帕金森病中起相反的作用,并且还有许多部分尚未确认
Smart Images

Figure FDA0004998950950000011 
Figure FDA0004998950950000021 
Figure FDA0004998950950000022
Abstract
Description
Technical Field
[0001] The present invention relates to a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, and in particular to a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, which comprises a compound that inhibits Pin1 (peptidyl prolyl cis-trans isomerase NIMA interacting protein 1) as an active ingredient. Background Art
[0002] Pin1 (Peptidylprolyl cis-trans isomerase NIMA interacting protein 1), a prolyl isomerase, is an enzyme that catalyzes the cis / trans isomerization of proline residue amides by binding to phosphorylated Ser / Thr-Pro sites (Lu, et al., Science 1999, 283(5406): 1325-8). During intracellular signal transduction, serine (Ser), threonine (Thr), and tyrosine (Tyr) residues of proteins are phosphorylated. After this phosphorylation, Pin1 changes the structure of various proteins through the cis / trans isomerization of proline residue amides, allowing these proteins to initiate their functions in cells.
[0003] According to the research so far, it is known that Pin1 enzyme is involved in the onset and progression of inflammatory diseases, metabolic diseases and cancer. Specifically, it has been reported that Pin1 enzyme activates 56 oncogenes involved in tumor formation, such as β-catenin, AKT, AR, CyclinD1, Plk, NF-kB, Stat3, Myc, c-Jun, c-Fos, c-Myb, Raf-1, HIF-1, Nanog, Notch1, Oct4, etc., and inhibits the activity of 26 tumor suppressor genes such as ATR, Bax, Btk, FADD, Fbw7, PML, etc., thereby inducing cancer metastasis and cancer angiogenesis in the entire cancer development mechanism. Therefore, Pin1 protein is being extensively studied as a cancer diagnostic reagent, prognostic factor and a useful target for the development of new anticancer drugs (Nature Reviews Cancer 2016, 16: 463-478; Cell Detation and Disease 2018, 9: 883).
[0004] As reported by studies on surgical resection samples, Pin1 is known to be highly expressed in various types of cancer, such as colon cancer, cervical cancer, breast cancer, lung cancer, pancreatic cancer, gastric cancer, liver cancer, etc. In fact, transgenic mice expressing Pin1 have been reported to show a carcinogenic phenotype. In addition, it is known that mitotic arrest and apoptosis can be induced using specific inhibitors or siRNA, and the stem cell properties of cancer can be suppressed in cancer cells in which Pin1 is knocked out. Specifically, the Pin1 enzyme has the function of inducing breast cancer stem cell self-renewal, metastasis, and tumor formation.
[0005] When Pin1 is overexpressed, human mammary epithelial cells differentiate into pseudostem cells and undergo epithelial-mesenchymal transition. In other words, when cancer cells grow and metastasize aggressively, in order to break adhesion with surrounding cells and pass through blood vessels or lymphatic vessels, the binding between cells becomes loose, the cytoskeleton changes, and thus acquires mobility. The Pin1 enzyme is considered an important factor for stem cell self-renewal, which maintains the stability of Nanog, Oct4, and Myc proteins.
[0006] Although Pin1 is involved in many mechanisms in vivo as described above, Pin1 knockout mice are known to grow well without major problems. Therefore, it is expected that inhibiting Pin1 will not have a significant effect on humans. However, although there are reports that Pin1 can help treat Alzheimer's disease in the brain, there are reports that it plays the opposite role in Parkinson's disease, and there are many parts that have not yet been confirmed. In short, Pin1 plays a very important role in the occurrence of cancer as a whole, and inhibiting Pin1 in areas other than the brain is very useful for effectively and safely treating cancer.
[0007] In addition, it has been reported that when Pin1 is inhibited or Pin1 gene expression is knocked out, the production of prostaglandin E2 and nitric oxide stimulated by lipopolysaccharide (LPS) and nicotine is weakened, and the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) is also weakened, resulting in anti-inflammatory effects (Journal of Dental Research, 2015, 94 (2): 371-380). It is well known that when Pin1 is linked to CRTC2, the production of CBP-CRTC2-CREB complex that promotes gluconeogenesis is inhibited, so that CRTC2 can be regulated according to the expression level of Pin1, and may therefore be involved in the regulation of glucose metabolism (J. Biol. Chem., 2010, 285 (43): 33018-27). Therefore, drugs that affect Pin1 expression or activity can be used as therapeutic agents for inflammatory diseases or metabolic diseases such as diabetes.
[0008] Therefore, the present inventors conducted pharmaceutical chemical synthesis and biological and pharmacological evaluation of the synthesized compounds and found compounds that inhibit Pin1 activity. Thus, the present inventors found compounds that exhibit excellent anticancer effects by strongly inhibiting Pin1 and completed the present invention. In addition, based on the role of Pin1 in inflammatory and metabolic diseases, it is believed that the compounds of the present invention can be used as therapeutic agents for diseases. Summary of the invention
[0009] Technical issues
[0010] The object of the present invention is to provide a novel compound that inhibits Pin1 (peptidylprolyl cis-trans isomerase NIMA interacting protein 1), its isomers or pharmaceutically acceptable salts thereof.
[0011] Another object of the present invention is to provide a method for preparing the compound.
[0012] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, comprising the compound, its isomer or a pharmaceutically acceptable salt thereof as an active ingredient.
[0013] Technical Solution
[0014] In order to achieve the above object, in one aspect of the present invention, the present invention provides a compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof:
[0015] [Formula 1]
[0016]
[0017] (In Formula 1,
[0018] Ar is a 6-10 membered aryl group or a 5-10 membered heteroaryl group containing one or more heteroatoms selected from N, S and O;
[0019] R 1 and R 2 are independently hydrogen, halogen or a 5-8 membered heterocycloalkyl C containing at least one N 1-5 Alkoxy;
[0020] R 3 is hydrogen, halogen, unsubstituted or substituted straight or branched chain C 1-8 Alkoxy, unsubstituted or substituted straight chain or branched C 1-8 Alkyl, NR a1 R a2 OR a3 , where R a1 , R a2 and R a3are independently hydrogen, unsubstituted or substituted straight or branched chain C 1-8 alkyl, unsubstituted or substituted phenyl or 5-8 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O,
[0021] In this case, the substituted alkoxy, the substituted alkyl, the substituted phenyl and the substituted heteroaryl are independently substituted by one or more substituents selected from the following: 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 4-8 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, NR b1 R b2 , 3-6 membered cycloalkyl, halogen, hydroxyl and sulfonyl, or the substituted alkoxy and the substituted alkyl may be further substituted to form a 3-6 membered cycloalkyl with each independently substituted carbon,
[0022] The substituted heterocycloalkyl and the substituted heteroaryl are substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more halogen straight or branched chain C 1-5 Alkyl, linear or branched C 1-5 Alkylcarbonyl, NR b1 R b2 , halogen, hydroxy and oxo,
[0023] R b1 and R b2 are independently hydrogen, or a linear or branched C 1-6 alkyl;
[0024] L 1 for Where R c is hydrogen or L 2 Together with the nitrogen to which they are attached, they form a 5-8 membered heterocycloalkylene group containing N;
[0025] L 2 Single bond, straight chain or branched C 1-8 Alkylene, C 3-8 Cycloalkylene or phenylene which is unsubstituted or substituted by hydroxy and oxo;
[0026] Z is unsubstituted or substituted C 6-10 Aryl, unsubstituted or C fused to a 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O 3-8Cycloalkyl, 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, or 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O. 1-5 alkyl,
[0027] The substituted aryl may be halogen, phenyl, carboxyl, a 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, or a straight or branched C 1-8 Alkoxycarbonyl substitution,
[0028] In this case, the substituted heterocycloalkyl, the substituted heteroaryl and the substituted heteroarylalkyl are independently substituted by one or more selected from linear or branched C 1-5 Alkyl, linear or branched C 1-8 Alkoxy, phenyl, benzyl, halogen, hydroxy or oxo substituents.)
[0029] In another aspect of the present invention, a method for preparing a compound represented by Formula 1, the method comprising the step of preparing a compound represented by Formula 1 by reacting a compound represented by Formula 2 with a compound represented by Formula 3 as shown in the following Reaction Formula 1:
[0030] [Reaction 1]
[0031]
[0032] (In reaction formula 1, Ar, R 1 , R 2 , R 3 , L 1 , L 2 and Z is as defined in Formula 1 of claim 1,
[0033] J 1 is chlorosulfone or carboxyl; and
[0034] J 2 is an amine or piperidine. )
[0035] In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, comprising as an active ingredient a compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof.
[0036] In another aspect of the present invention, the present invention provides a method for preventing or treating cancer, inflammatory diseases or metabolic diseases, the method comprising the step of administering a pharmaceutical composition comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient to a subject in need thereof.
[0037] In another aspect of the present invention, the present invention provides use of a pharmaceutical composition comprising a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient in preventing or treating cancer, inflammatory diseases or metabolic diseases.
[0038] Beneficial Effects
[0039] Since the novel compound according to the present invention exhibits excellent anti-Pin1 inhibitory activity, a pharmaceutical composition comprising the compound as an active ingredient can be effectively used for preventing or treating cancer, inflammatory diseases or metabolic diseases. DETAILED DESCRIPTION OF THE INVENTION
[0041] Hereinafter, the present invention is described in detail.
[0042] In one aspect of the present invention, the present invention provides a compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof:
[0043] [Formula 1]
[0044]
[0045] (In Formula 1,
[0046] Ar is a 6-10 membered aryl group or a 5-10 membered heteroaryl group containing one or more heteroatoms selected from N, S and O;
[0047] R 1 and R 2 are independently hydrogen, halogen or a 5-8 membered heterocycloalkyl C containing at least one N 1-5 Alkoxy;
[0048] R 3 is hydrogen, halogen, unsubstituted or substituted straight or branched chain C 1-8 Alkoxy, unsubstituted or substituted straight chain or branched C 1-8 Alkyl, NR a1 R a2 OR a3 , where R a1 , R a2 and R a3 are independently hydrogen, unsubstituted or substituted straight or branched chain C 1-8 alkyl, unsubstituted or substituted phenyl or 5-8 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O,
[0049] In this case, the substituted alkoxy, the substituted alkyl, the substituted phenyl and the substituted heteroaryl are independently substituted by one or more substituents selected from the following: 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 4-8 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, NR b1 R b2 , 3-6 membered cycloalkyl, halogen, hydroxyl and sulfonyl, or the substituted alkoxy and the substituted alkyl may be further substituted to form a 3-6 membered cycloalkyl with each independently substituted carbon,
[0050] The substituted heterocycloalkyl and the substituted heteroaryl are substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more halogen straight or branched chain C 1-5 Alkyl, linear or branched C 1-5 Alkylcarbonyl, NR b1 R b2 , halogen, hydroxy and oxo,
[0051] R b1 and R b2 are independently hydrogen, or a linear or branched C 1-6 alkyl;
[0052] L 1 for Where R c is hydrogen or L 2 Together with the nitrogen to which they are attached, they form a 5-8 membered heterocycloalkylene group containing N;
[0053] L 2 Single bond, straight chain or branched C 1-8 Alkylene, C 3-8 Cycloalkylene or phenylene which is unsubstituted or substituted by hydroxy and oxo;
[0054] Z is unsubstituted or substituted C 6-10 Aryl, unsubstituted or C fused to a 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O 3-8 Cycloalkyl, 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, or 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O. 1-5 alkyl,
[0055] The substituted aryl may be halogen, phenyl, carboxyl, a 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, or a straight or branched C1-8 Alkoxycarbonyl substitution,
[0056] In this case, the substituted heterocycloalkyl, the substituted heteroaryl and the substituted heteroarylalkyl are independently substituted by one or more selected from linear or branched C 1-5 Alkyl, linear or branched C 1-8 Alkoxy, phenyl, benzyl, halogen, hydroxy or oxo substituents.)
[0057] The compound according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein:
[0058] Ar is a 6-10 membered aryl group or a 5-6 membered heteroaryl group containing one or more heteroatoms selected from N, S and O;
[0059] R 1 and R 2 are independently hydrogen or fluorine;
[0060] R 3 is hydrogen, bromine, unsubstituted or substituted straight or branched chain C 1-6 Alkoxy, unsubstituted or substituted straight chain or branched C 1-6 Alkyl, NR a1 R a2 OR a3 , where R a1 , R a2 and R a3 are independently hydrogen, unsubstituted or substituted straight or branched chain C 1-6 alkyl, unsubstituted or substituted phenyl or 5-7 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O,
[0061] In this case, the substituted alkoxy, the substituted alkyl, the substituted phenyl and the substituted heteroaryl are independently substituted by one or more substituents selected from the following: 4-7 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 4-7 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, NR b1 R b2 , 3-5 membered cycloalkyl, fluorine, bromine, hydroxyl and sulfonyl, or the substituted alkoxy and the substituted alkyl may be further substituted to form a 3-5 membered cycloalkyl with each independently substituted carbon,
[0062] The substituted heterocycloalkyl and the substituted heteroaryl are substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more halogen straight or branched chain C 1-4 Alkyl, linear or branched C 1-4 Alkylcarbonyl, NR b1 Rb2 , chlorine, fluorine, bromine, hydroxy and oxo,
[0063] R b1 and R b2 are independently hydrogen, or a linear or branched C 1-3 alkyl;
[0064] L 1 for Where R c is hydrogen or L 2 Together with the nitrogen to which they are attached they form a piperidinylene;
[0065] L 2 Single bond, straight chain or branched C 1-6 Alkylene, C 4-6 Cycloalkylene or phenylene which is unsubstituted or substituted by hydroxy and oxo;
[0066] Z is unsubstituted or substituted C 6-9 Aryl, unsubstituted or C fused to a 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O 4-7 Cycloalkyl, 5-6 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 6-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, or 6-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O. 1-4 alkyl,
[0067] The substituted aryl is replaced by chlorine, phenyl, carboxyl, morpholinyl or straight or branched C 1-3 Alkoxycarbonyl substitution,
[0068] In this case, the substituted heterocycloalkyl, the substituted heteroaryl and the substituted heteroarylalkyl are independently substituted by one or more selected from linear or branched C 1-4 Alkyl, linear or branched C 1-4 The alkylene group may be substituted with alkoxy, benzyl, phenyl, fluorine, chlorine, bromine, hydroxyl or oxo substituents.
[0069] The compound according to claim 1, its isomer or pharmaceutically acceptable salt thereof, wherein:
[0070] Ar is phenyl, naphthyl, pyridine or thiazole;
[0071] R 1 and R 2 are independently hydrogen or fluorine;
[0072] R 3 is hydrogen, bromine, unsubstituted or substituted straight or branched chain C 1-5Alkoxy, unsubstituted or substituted straight chain or branched C 1-5 Alkyl, NR a1 R a2 OR a3 , where R a1 , R a2 and R a3 are independently hydrogen, unsubstituted or substituted straight or branched chain C 1-5 alkyl, unsubstituted or substituted phenyl or 5-6 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O,
[0073] In this case, the substituted alkoxy, the substituted alkyl, the substituted phenyl and the substituted heteroaryl are independently substituted by one or more substituents selected from the following: 4-7 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 5-7 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, NR b1 R b2 , 3-4 membered cycloalkyl, fluorine, bromine, hydroxyl and sulfonyl, or the substituted alkoxy and the substituted alkyl may be further substituted to form a cyclopropyl with each independently substituted carbon,
[0074] The substituted heterocycloalkyl and the substituted heteroaryl are substituted by one or more substituents selected from the following: unsubstituted or one or more fluorine-substituted straight or branched chain C 1-3 Alkyl, linear or branched C 1-4 Alkylcarbonyl, NR b1 R b2 , chlorine, fluorine, bromine, hydroxy and oxo,
[0075] R b1 and R b2 are independently hydrogen, methyl or ethyl;
[0076] L 1 for Where R c is hydrogen or L 2 Together with the nitrogen to which they are attached they form a piperidinylene;
[0077] L 2 is a single bond, unsubstituted or substituted with one of hydroxyl and oxo, straight chain or branched C 1-4 Alkylene, cyclohexylene or phenylene;
[0078] Z is unsubstituted or substituted phenyl, cyclohexyl, naphthyl, a C fused to a 5-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O. 5-6cycloalkyl, 5-6 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, 6-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O, or 6-9 membered unsubstituted or substituted heteroaryl containing one or more heteroatoms selected from N, S and O. 1-3 alkyl,
[0079] The substituted phenyl is substituted by chlorine, phenyl, carboxyl, morpholinyl or methoxycarbonyl,
[0080] In this case, the substituted heterocycloalkyl, the substituted heteroaryl and the substituted heteroarylalkyl are independently substituted by one or more selected from linear or branched C 1-3 The alkyl group may be substituted with alkyl, methoxy, benzyl, phenyl, fluoro, chloro, bromo, hydroxy or oxo substituents.
[0081] The compound according to claim 1, its isomer or a pharmaceutically acceptable salt thereof, wherein:
[0082] Ar is phenyl, naphthyl, pyridine or thiazole;
[0083] R 1 and R 2 are independently hydrogen or fluorine;
[0084] R 3 For hydrogen, bromine,
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093] L 1 for L 2 For a single key,
[0094]
[0095] Z is
[0096]
[0097]
[0098]
[0099] The compound according to claim 1, its isomer or a pharmaceutically acceptable salt thereof, wherein the compound represented by Formula 1 is selected from the following compounds:
[0100] <1> N-(3-([1,1'-biphenyl]-4-yl)propyl)-4-butoxybenzenesulfonamide;
[0101] <2> 4-Butoxy-N-(3-(4-isopropylpiperazin-1-yl)propyl)benzenesulfonamide;
[0102] <3> 4-Butoxy-N-(3-(4-chlorophenyl)propyl)benzenesulfonamide;
[0103] <4> 4-Butoxy-N-(3-cyclohexylpropyl)benzenesulfonamide;
[0104] <5> 4-Butoxy-N-(3-(pyridin-3-yl)propyl)benzenesulfonamide;
[0105] <6> 4-Butoxy-N-(3-morpholinopropyl)benzenesulfonamide;
[0106] <7> 4-Butoxy-N-(4-morpholinophenethyl)benzenesulfonamide;
[0107] <8> 4-(2-(4-Butoxyphenylsulfonamido)ethyl)benzoic acid;
[0108] <9> Methyl 4-(2-(4-butoxyphenylsulfonamido)ethyl)benzoate;
[0109] <10> N-(2-(4-Benzylpiperidin-1-yl)ethyl)-4-butoxybenzenesulfonamide;
[0110] <11> 4-Butoxy-N-(3-hydroxy-3-phenylpropyl)benzenesulfonamide;
[0111] <12> 4-Butoxy-N-(3-oxo-3-phenylpropyl)benzenesulfonamide;
[0112] <13> 4-Butoxy-N-(3-(2-oxopyrrolidin-1-yl)propyl)benzenesulfonamide;
[0113] <14> 4-(3-(Dimethylamino)propoxy)-N-phenethylbenzenesulfonamide;
[0114] <15> 4-(3-(Dimethylamino)propoxy)-N-(3-phenylpropyl)benzenesulfonamide;
[0115] <16> Methyl 4-(2-(4-(3-(dimethylamino)propoxy)phenylsulfonylamino)ethyl)benzoate 16;
[0116] <17> 4-(2-(4-(3-(dimethylamino)propyloxy)phenylsulfonylamino)ethyl)benzoic acid;
[0117] <18> 4-(3-(Dimethylamino)propoxy)-N-(3-(2-oxopyrrolidin-1-yl)propyl)benzenesulfonamide;
[0118] <19> 4-Butoxy-N-(3-(naphthalen-1-yl)propyl)benzenesulfonamide;
[0119] <20> N-(3-(1H-indol-3-yl)propyl)-4-butoxybenzenesulfonamide;
[0120] <21> N-(3-(1H-indol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)benzenesulfonamide;
[0121] <22> N-(3-(1H-indol-3-yl)propyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide;
[0122] <23> N-(2-(1H-benzo[d]imidazol-2-yl)ethyl)-4-butoxybenzenesulfonamide;
[0123] <24> N-(2-(1H-indol-3-yl)ethyl)-4-butoxybenzenesulfonamide;
[0124] <25> N-(2-(1H-indol-2-yl)ethyl)-4-butoxybenzenesulfonamide;
[0125] <26> N-(3-(1H-indol-3-yl)propyl)-4-(isopentyloxy)benzenesulfonamide;
[0126] <27> N-(3-(1H-indol-3-yl)propyl)-4-(pentyloxy)benzenesulfonamide;
[0127] <28> N-(3-(1H-benzo[d]imidazol-2-yl)propyl)-4-butoxybenzenesulfonamide;
[0128] <29> 4-Butoxy-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)benzenesulfonamide;
[0129] <30> N-(3-(1H-indol-3-yl)propyl)-4-(3-morpholinopropoxy)benzenesulfonamide;
[0130] <31> N-(3-(1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0131] <32> N-(3-(1H-indol-1-yl)propyl)-4-butoxybenzenesulfonamide;
[0132] <33> N-(3-(1H-benzo[d]imidazol-1-yl)propyl)-4-butoxybenzenesulfonamide;
[0133] <34> N-(3-(1H-benzo[d]imidazol-1-yl)propyl)-4-butoxybenzenesulfonamide;
[0134] <35> N-(3-(1H-indol-3-yl)propyl)-4-(3-(diethylamino)propoxy)benzenesulfonamide;
[0135] <36> N-(3-(1H-indol-3-yl)propyl)-4-(3-(4-ethylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0136] <37> N-(2-(1H-benzo[d]imidazol-2-yl)ethyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide;
[0137] <38> N-(2-(1H-indol-2-yl)ethyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide;
[0138] <39> N-(3-(1H-indol-1-yl)propyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide;
[0139] <40> N-(3-(1H-benzo[d]imidazol-1-yl)propyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide;
[0140] <41> N-(3-(1H-indol-1-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0141] <42> N-(3-(1H-benzo[d]imidazol-1-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0142] <43> N-(3-(1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)propoxy)benzenesulfonamide;
[0143] <44> N-(3-(1H-indol-3-yl)propyl)-4-(3-(2-oxopyrrolidin-1-yl)propoxy)benzenesulfonamide;
[0144] <45> N-(3-(1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propyloxy)benzenesulfonamide;
[0145] <46> 4-(3-(Dimethylamino)propoxy)-N-(3-(1-methyl-1H-indol-3-yl)propyl)benzenesulfonamide;
[0146] <47> N-(3-(1H-indol-3-yl)propyl)-4-bromobenzenesulfonamide;
[0147] <48> N-(3-(1H-indol-3-yl)propyl)-4-(3-(4-isopropylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0148] <49> N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0149] <50> N-(2-(1H-indol-3-yl)ethyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0150] <51> N-(2-(1H-indol-3-yl)ethyl)-4-(3-(4-isopropylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0151] <52> N-(3-(1H-indol-3-yl)propyl)-4-(2-(4-methylpiperazin-1-yl)ethoxy)benzenesulfonamide;
[0152] <53> N-(3-(1H-indol-3-yl)propyl)-4-(2-(4-isopropylpiperazin-1-yl)ethoxy)benzenesulfonamide;
[0153] <54> N-(2-(2-methyl-1H-indol-3-yl)ethyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0154] <55> N-(3-(1H-indol-3-yl)propyl)-4-(2-(1-methylpiperidin-4-yl)ethoxy)benzenesulfonamide;
[0155] <56> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0156] <57> 3-(1-((4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)sulfonyl)piperidin-4-yl)-1H-indole;
[0157] <58> N-(3-(2-methyl-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0158] <59> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonamide;
[0159] <60> N-(3-(1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonamide;
[0160] <61> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0161] <62> N-(3-(1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0162] <63> 4-(3-(4-ethylpiperazin-1-yl)propoxy)-N-(3-(5-fluoro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0163] <64> 5-methoxy-3-(1-((4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)sulfonyl)piperidin-4-yl)-1H-indole;
[0164] <65> 5-methyl-3-(1-((4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)sulfonyl)piperidin-4-yl)-1H-indole;
[0165] <66> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0166] <67> N-(3-(5-methyl-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0167] <68> N-(3-(5-methoxy-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0168] <69> N-(3-(1H-indol-3-yl)propyl)-4-(3-(4-hydroxypiperidin-1-yl)propyloxy)benzenesulfonamide;
[0169] <70> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0170] <71> 5-Fluoro-3-(1-((4-(3-(4-methylpiperazin-1-yl)propoxy)phenyl)sulfonyl)piperidin-4-yl)-1H-indole;
[0171] <72> 4-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propoxy)-N-(3-(5-fluoro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0172] <73> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(4-isobutyrylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0173] <74> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)propoxy)benzenesulfonamide;
[0174] <75> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-hydroxypiperidin-1-yl)propoxy)benzenesulfonamide;
[0175] <76> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)propoxy)benzenesulfonamide;
[0176] <77> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-(methylamino)azetidin-1-yl)propoxy)benzenesulfonamide;
[0177] <78> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-chloropiperidin-1-yl)propoxy)benzenesulfonamide;
[0178] <79> N-(3-(5-chloro-1H-indol-3-yl)propyl)-6-(3-(piperazin-1-yl)propoxy)pyridine-3-sulfonamide;
[0179] <80> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-fluoropiperidin-1-yl)propoxy)benzenesulfonamide;
[0180] <81> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-(trifluoromethyl)piperidin-1-yl)propoxy)benzenesulfonamide;
[0181] <82> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4,4-difluoropiperidin-1-yl)propoxy)benzenesulfonamide;
[0182] <83> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methyl-1,4-diazepan-1-yl)propoxy)benzenesulfonamide;
[0183] <84> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)propoxy)benzenesulfonamide;
[0184] <85> N-(3-(1H-indol-3-yl)cyclohexyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0185] <86> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)naphthalene-1-sulfonamide;
[0186] <87> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)propoxy)benzenesulfonamide;
[0187] <88> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperidin-4-yl)propyl)amino)benzenesulfonamide;
[0188] <89> N-(3-(1H-indol-3-yl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0189] <90> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-1-yl)butyl)benzenesulfonamide;
[0190] <91> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperazin-1-yl)butyl)benzenesulfonamide;
[0191] <92> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonamide;
[0192] <93> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-4-yl)propoxy)benzenesulfonamide;
[0193] <94> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-(3-(piperidin-4-yl)propoxy)benzenesulfonamide;
[0194] <95> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-(3-(piperidin-1-yl)propoxy)benzenesulfonamide;
[0195] <96> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0196] <97> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(piperidin-4-yl)propoxy)benzenesulfonamide;
[0197] <98> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzenesulfonamide;
[0198] <99> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-4-yl)butyl)benzenesulfonamide;
[0199] <100> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(pyrrolidin-1-yl)propoxy)benzenesulfonamide;
[0200] <101> 4-(3-(azepan-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0201] <102> 4-(3-(1,4-diazepan-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0202] <103> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0203] <104> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0204] <105> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-hydroxypiperidin-1-yl)propoxy)benzenesulfonamide;
[0205] <106> 4-(3-(1,4-diazepan-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluorobenzenesulfonamide;
[0206] <107> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0207] <108> (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0208] <109> (S)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0209] <110> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0210] <111> (S)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3,4-dimethylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0211] <112> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(4-methylpiperazin-1-yl)butyl)benzenesulfonamide;
[0212] <113> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperazin-1-yl)propyl)amino)benzenesulfonamide;
[0213] <114> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperidin-1-yl)propyl)amino)benzenesulfonamide;
[0214] <115> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(1-methylpiperidin-4-yl)butyl)benzenesulfonamide;
[0215] <116> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((1-((4-methylpiperazin-1-yl)methyl)cyclopropyl)methoxy)benzenesulfonamide;
[0216] <117> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((1-(piperazin-1-ylmethyl)cyclopropyl)methoxy)benzenesulfonamide;
[0217] <118> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)phenoxy)benzenesulfonamide;
[0218] <119> 4-(3-Bromophenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0219] <120> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)phenoxy)benzenesulfonamide;
[0220] <121> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)phenoxy)benzenesulfonamide;
[0221] <122> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methyl-1,4-diazepan-1-yl)phenoxy)benzenesulfonamide;
[0222] <123> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-methylpiperazin-1-yl)phenyl)amino)benzenesulfonamide;
[0223] <124> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperazin-1-yl)phenyl)amino)benzenesulfonamide;
[0224] <125> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(4-methylpiperazin-1-yl)pyrimidin-2-yl)amino)benzenesulfonamide;
[0225] <126> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-morpholinophenyl)amino)benzenesulfonamide;
[0226] <127> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(piperazin-1-yl)pyrimidin-2-yl)amino)benzenesulfonamide;
[0227] <128> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-morpholinophenoxy)benzenesulfonamide;
[0228] <129> 4-(3-(1,4-diazepan-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0229] <130> 4-(3,5-bis(4-methylpiperazin-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0230] <131> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((6-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide;
[0231] <132> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((6-(piperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide;
[0232] <133> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide;
[0233] <134> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(piperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide;
[0234] <135> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(pyrrolidin-1-yl)phenoxy)benzenesulfonamide;
[0235] <136> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-hydroxypiperidin-1-yl)phenoxy)benzenesulfonamide;
[0236] <137> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-fluoro-5-(4-methylpiperazin-1-yl)phenoxy)benzenesulfonamide;
[0237] <138> 4-(3-Bromo-5-(4-methylpiperazin-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0238] <139> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-hydroxypiperidin-1-yl)phenyl)amino)benzenesulfonamide;
[0239] <140> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((6-chloro-4-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide;
[0240] <141> 4-((4,6-bis(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0241] <142> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(4-methylpiperazin-1-yl)phenyl)amino)benzenesulfonamide;
[0242] <143> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzamide;
[0243] <144> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzamide;
[0244] <145> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(methylsulfonyl)propoxy)benzenesulfonamide;
[0245] <146> N-(3-(5-chloro-1H-indol-3-yl)propyl)-2-((3-(piperazin-1-yl)propyl)amino)thiazole-5-sulfonamide;
[0246] <147> N-(3-(5-chloro-2-methyl-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0247] <148> 4-(4-(1H-imidazol-1-yl)butyl)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0248] <149> N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0249] <150> N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0250] <151> N-(4-(5-chloro-1H-indol-3-yl)butan-2-yl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0251] <152> N-(4-(5-chloro-1H-indol-3-yl)butan-2-yl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0252] <153> N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0253] <154> N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0254] <155> N-(3-(5-phenyl-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0255] <156> 4-(3-(4-methylpiperazin-1-yl)propoxy)-N-(3-(5-phenyl-1H-indol-3-yl)propyl)benzenesulfonamide;
[0256] <157> N-(3-(5-chloro-2-methyl-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0257] <158> N-(2-(5-chloro-1H-indol-3-yl)ethyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0258] <159> N-(2-(5-chloro-1H-indol-3-yl)ethyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0259] <160> 4-(3-(1H-1,2,4-triazol-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide;
[0260] <161> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(2-methyl-1H-imidazol-1-yl)propoxy)benzenesulfonamide;
[0261] <162> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methyl-3-oxopiperazin-1-yl)propoxy)benzenesulfonamide;
[0262] <163> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-oxopiperazin-1-yl)propoxy)benzenesulfonamide;
[0263] <164> N-(3-(5,7-dichloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0264] <165> N-(3-(5,7-dichloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0265] <166> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4,5-dichloro-1H-imidazol-1-yl)propoxy)benzenesulfonamide;
[0266] <167> N-(3-(5-chloro-1H-indazol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0267] <168> N-(3-(5-chloro-1H-indazol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0268] <169> N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0269] <170> N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0270] <171> (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0271] <172> (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(2-hydroxy-3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0272] <173> (S)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0273] <174> (S)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(2-hydroxy-3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0274] <175> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4,5-dimethyl-1H-imidazol-1-yl)propoxy)benzenesulfonamide;
[0275] <176> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(2,4,5-trimethyl-1H-imidazol-1-yl)propoxy)benzenesulfonamide;
[0276] <177> N-((6-chloro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0277] <178> N-((6-chloro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0278] <179> N-(3-(5-chloro-1H-indol-3-yl)cyclohexyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0279] <180> N-(3-(5-chloro-1H-indol-3-yl)cyclohexyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0280] <181> N-(2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0281] <182> N-(2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)phenyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0282] <183> N-(3-(5,6-dichloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0283] <184> N-(3-(5,6-dichloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0284] <185> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(pyridin-4-yloxy)propyl)benzenesulfonamide;
[0285] <186> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propyl)benzenesulfonamide;
[0286] <187> N-((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide;
[0287] <188> N-((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide;
[0288] <189> 4-(3-(4-methylpiperazin-1-yl)propoxy)-N-((2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)benzenesulfonamide;
[0289] <190> 4-(3-(Piperazin-1-yl)propoxy)-N-((2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)benzenesulfonamide.
[0290] The compound represented by Formula 1 of the present invention can be used in the form of a pharmaceutically acceptable salt, wherein the salt is preferably an acid addition salt formed by a pharmaceutically acceptable free acid. The acid addition salt herein can be obtained from an inorganic acid, a non-toxic organic acid or an organic acid, the inorganic acid being for example hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid and phosphorous acid; the non-toxic organic acid being for example aliphatic mono / dicarboxylic acid esters, phenyl-substituted alkanoic acid esters, hydroxyalkanoic acid esters, alkanedioic acid esters, aromatic acids and aliphatic / aromatic sulfonic acids; the organic acid being for example acetic acid, benzoic acid, citric acid, lactic acid, maleic acid, gluconic acid, methanesulfonic acid, 4-toluenesulfonic acid, tartaric acid and fumaric acid. Examples of pharmaceutically nontoxic salts are sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, fluorides, acetates, propionates, decanoates, octanoates, acrylates, formates, isobutyrates, decanoates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, carbarates, fumarates, malates, butyne-1,4-dioic acid salt, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate.
[0291] The acid addition salt of the present invention can be prepared by conventional methods known to those skilled in the art. For example, the derivative represented by Formula 1 is dissolved in an organic solvent such as methanol, ethanol, acetone, dichloromethane and acetonitrile, and an organic acid or an inorganic acid is added thereto to induce precipitation. Then, the precipitate is filtered and dried to obtain a salt. Alternatively, the solvent and excess acid are distilled under reduced pressure and dried to obtain a salt. Alternatively, the precipitate is crystallized in an organic solvent to obtain the same product.
[0292] Pharmaceutically acceptable metal salts can be prepared using a base. Alkali metal or alkaline earth metal salts are obtained by the following method: dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution; filtering the insoluble composite salt; evaporating the remaining solution and drying. In this case, the metal salt is preferably prepared in the form of a pharmaceutically suitable sodium salt, potassium salt or calcium salt. The corresponding silver salt is prepared by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (e.g., silver nitrate).
[0293] Furthermore, the present invention includes not only the compound represented by Formula 1 and pharmaceutically acceptable salts thereof, but also solvates, isomers, hydrates and the like that can be prepared therefrom.
[0294] The term "isomer" refers to a compound of the present invention or a salt thereof having the same chemical formula or molecular formula, but different in structure or space. Such isomers include structural isomers such as tautomers, R or S isomers with asymmetric carbon centers; stereoisomers such as geometric isomers (trans, cis); and optical isomers. All these isomers and mixtures thereof are also included within the scope of the present invention.
[0295] The compound represented by Formula 1 of the present invention can be prepared according to the preparation methods shown in the following examples, but this is only an example and is not limited thereto, and each preparation step can be performed using a method known to those skilled in the art.
[0296] In another aspect of the present invention, the present invention provides a method for preparing a compound represented by Formula 1, the method comprising the step of preparing a compound represented by Formula 1 by reacting a compound represented by Formula 2 with a compound represented by Formula 3, as shown in the following Reaction Formula 1.
[0297] [Reaction 1]
[0298]
[0299] In reaction formula 1, Ar, R 1 , R 2 , R 3 , L 1 , L 2 and Z are as defined above in Formula 1, J 1 is chlorosulfone or carboxyl; and
[0300] J 2 is an amine or a piperidine.
[0301] Hereinafter, the preparation method shown in Reaction Scheme 1 is described in detail.
[0302] In the method for preparing the compound represented by Formula 1 of the present invention, the step of Reaction Formula 1 is a step of preparing the compound represented by Formula 1 by reacting the compound represented by Formula 2 with the compound represented by Formula 3. Specifically, this is a step in which the compound represented by Formula 1 is formed by reacting the chlorosulfone or carboxyl group of the compound represented by Formula 2 with the amine of the compound represented by Formula 3.
[0303] At this time, as long as the step is a method for preparing a compound represented by Formula 1, and is included in the scope of the present invention, the step is not particularly limited. The compound represented by Formula 2 can be understood as a compound having a group (such as sulfone) that is easy to accept electrons and a leaving group (such as chlorine) that is easy to react, or a compound having a carboxyl group that can react with an amine to form an amide, and the compound represented by Formula 3 can be understood as an amine that can be nucleophilically substituted or can undergo an amide formation reaction, but is not always limited thereto. The compound having a group and a leaving group that are easy to accept electrons undergoes nucleophilic substitution with an amine having sufficient nucleophilicity to react with each other, or a carboxyl group undergoes an amide formation reaction with an amine to prepare the final compound.
[0304] In more detail, it can be understood with reference to the preparation methods of the example compounds of the present invention, but various reaction conditions (reaction conditions that can be considered by those skilled in the art of organic synthesis, such as reaction temperature, time, atmospheric conditions, pressure conditions, etc.) can be changed. It can be understood that the present invention is not limited thereto, and the compounds and derivatives thereof used in each step include modified derivatives that can be modified by simply modifying, changing or removing substituents in addition to those disclosed in the present invention.
[0305] As a preferred embodiment of the preparation method, the preparation methods disclosed in the following Examples 1 to 190 can be exemplified, but the present invention is not limited thereto.
[0306] In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, comprising as an active ingredient a compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof.
[0307] The compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention may inhibit Pin1 (peptidylprolyl cis-trans isomerase NIMA interacting protein 1).
[0308] Pin1, a prolyl isomerase, is an enzyme that catalyzes the cis / trans isomerization of proline residue amides by binding to phosphorylated Ser / Thr-Pro sites. Based on studies to date, Pin1 enzymes are known to be involved in the onset and progression of inflammatory diseases, metabolic diseases, and cancer.
[0309] Specifically, the Pin1 enzyme has been reported to activate 56 oncogenes involved in tumor formation and inhibit the activities of 26 tumor suppressor genes, thereby inducing cancer metastasis and cancer angiogenesis in the overall cancer development mechanism.
[0310] In addition, it has been reported that when Pin1 is inhibited or Pin1 gene expression is knocked out, the production of prostaglandin E2 and nitric oxide stimulated by lipopolysaccharide (LPS) and nicotine is attenuated, and the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) is also attenuated, resulting in an anti-inflammatory effect.
[0311] It is known that when Pin1 is linked to CRTC2, the production of the CBP-CRTC2-CREB complex that promotes gluconeogenesis is inhibited, so that CRTC2 can be regulated according to the expression level of Pin1 and may therefore be involved in the regulation of glucose metabolism.
[0312] Therefore, drugs that affect the expression or activity of Pin1 may be used as therapeutic agents for cancer, inflammatory diseases, or metabolic diseases such as diabetes.
[0313] Therefore, the compound represented by Formula 1 of the present invention, its isomer or a pharmaceutically acceptable salt thereof can be effectively used as a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases comprising the same as an active ingredient.
[0314] The cancer may be at least one selected from the group consisting of pseudomyxoma, intrahepatic bile duct cancer, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, male breast cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullary cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, renal cancer, kidney cancer. cancer), heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureter cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric stump cancer, gastrointestinal stromal cancer, Wilms cancer, breast cancer, sarcoma, penile cancer, pharyngeal cancer, chorionic villus disease of pregnancy, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectoid cancer, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer, and thymus cancer.
[0315] The inflammatory disease can be one selected from the following: arthritis, encephalomyelitis, meningitis, peritonitis, osteomyelitis, encephalitis, ankylosing spondylitis, vasculitis, uveitis, ileitis, atherosclerosis, myositis, leukocyte damage, inflammatory bowel disease, ulcerative colitis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, gout, vasculitis, non-alcoholic fatty hepatitis, primary sclerosing cholangitis, nephritis, intraperitoneal disease, sepsis, systemic inflammatory response syndrome, myocardial infarction, allergic disease, asthma, atopic dermatitis, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, chronic obstructive pulmonary disease and periodontitis.
[0316] The metabolic disease may be at least one selected from the group consisting of obesity, diabetes, hypertension, hyperlipidemia, hypercholesterolemia, arteriosclerosis, fatty liver, gout, stroke and heart disease.
[0317] The term "prevention" used in the present invention refers to any effect of inhibiting or delaying the onset of a neurological disorder by administering the pharmaceutical composition according to the present invention to a subject.
[0318] The term "treatment" used in the present invention refers to any effect of improving or benefiting the symptoms of a neurological disorder by administering the pharmaceutical composition according to the present invention to a subject.
[0319] When the composition of the present invention is used as a medicine, the pharmaceutical composition comprising the compound represented by Formula 1, its isomer or a pharmaceutically acceptable salt thereof as an active ingredient can be formulated as follows and administered in various oral or parenteral forms during clinical administration, but is not always limited thereto.
[0320] Examples of preparations for oral administration include tablets, pills, hard / soft capsules, solutions, suspensions, emulsions, syrups, granules, elixirs and lozenges. These preparations can also include diluents (e.g., lactose, glucose, sucrose, mannitol, sorbitol, cellulose and / or glycine) and lubricants (e.g., silicon dioxide, talc, stearate and its magnesium salt or calcium salt and / or polyethylene glycol) in addition to active ingredients. Tablets can include binding agents such as magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinyl pyrrolidone, and if necessary, disintegrants such as starch, agarose, alginic acid or its sodium salt or azeotropic mixture and / or absorbents, coloring agents, spices and sweeteners can also be included.
[0321] When the compound represented by Formula 1, its isomer or a pharmaceutically acceptable salt thereof is used as a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, it may be administered as a single therapeutic agent or may be used in combination with other therapeutic agents.
[0322] The pharmaceutical composition comprising the compound of Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient can be administered parenterally, including subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection.
[0323] In order to prepare a compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof as a preparation for parenteral administration, the compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof is mixed with a stabilizer or a buffer in water to prepare a solution or a suspension, which is then formulated into an ampoule or a vial. The composition herein may be sterile and additionally contain a preservative, a stabilizer, a wettable powder or an emulsifier, a salt for adjusting osmotic pressure and / or a buffer and other therapeutically useful substances, and the composition may be formulated according to conventional methods such as dispersion and gelation.
[0324] The dosage of the pharmaceutical composition containing the compound represented by Formula 1 as an active ingredient to the human body can be determined according to the formulation method, age, body weight, sex, administration method, health status and severity of the disease. The preferred dosage of the composition of the present invention is 0.001 to 1000 kg / kg per day, and it can be administered orally or parenterally several times a day, or preferably 1 to 3 times a day, according to the judgment of the doctor or pharmacist.
[0325] The pharmaceutical composition of the present invention can be used as a single preparation. The pharmaceutical composition of the present invention can also be prepared and used as a combined preparation further comprising one or more other therapeutic agents.
[0326] In another aspect of the present invention, the present invention provides a method for treating cancer, inflammatory diseases or metabolic diseases, the method comprising the step of administering the pharmaceutical composition to a subject in need thereof. The pharmaceutical composition refers to a pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, comprising a compound shown in Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
[0327] In another aspect of the present invention, the present invention provides use of a pharmaceutical composition comprising a compound represented by Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient in preventing or treating cancer, inflammatory diseases or metabolic diseases. DETAILED DESCRIPTION
[0328] Hereinafter, the present invention will be described in detail by way of examples and experimental examples.
[0329] However, the following embodiments and experimental examples are only used to illustrate the present invention, and the contents of the present invention are not limited thereto.
[0330] <Example 1> Preparation of N-(3-([1,1'-biphenyl]-4-yl)propyl)-4-butoxybenzenesulfonamide
[0331]
[0332] Step 1: Preparation of (E)-4-(2-isocyanovinyl)-1,1'-biphenyl
[0333]
[0334] Sodium hydride (60% wt, 0.263 g, 6.59 mmol) was dissolved in anhydrous tetrahydrofuran (13 ml), and diethyl (cyanomethyl)phosphonate (0.977 ml, 6.04 mmol) was added dropwise at 0°C. [1,1'-biphenyl]-4-carboxaldehyde (1 g, 5.49 mmol) was added dropwise to the reaction solution, and then stirred at room temperature for 30 minutes. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. As a result, a white solid (E)-4-(2-isocyanovinyl)-1,1'-biphenyl was obtained without further purification.
[0335] Step 2: Preparation of 3-([1,1'-biphenyl]-4-yl)propionitrile
[0336]
[0337] The compound prepared in step 1 above (1.126 g, 5.49 mmol) was dissolved in ethyl acetate: methanol (1: 1) (24 ml), Pd / C (10% wt) was added dropwise thereto at 0°C, and then stirred at room temperature for 12 hours in a hydrogen atmosphere. After the reaction was completed, the reaction mixture was filtered with diatomaceous earth, and the solvent was removed under reduced pressure. As a result, a white solid 3-([1,1'-biphenyl]-4-yl)propionitrile was obtained without further purification.
[0338] Step 3: Preparation of 3-([1,1'-biphenyl]-4-yl)propan-1-amine
[0339]
[0340] The compound 3-([1,1'-biphenyl]-4-yl)propionitrile (1.137 g, 5.49 mmol) synthesized in step 2 above was dissolved in anhydrous tetrahydrofuran (10 ml), 1M lithium aluminum hydride (10.97 ml, 10.97 mmol) was added dropwise thereto at 0°C, and then stirred at room temperature for 2 hours. The reaction was terminated by adding water dropwise, the reaction mixture was filtered with a filter, and the solvent was removed under reduced pressure. As a result, a viscous yellow compound 3-([1,1'-biphenyl]-4-yl)propane-1-amine was obtained without further purification.
[0341] Step 4: Preparation of N-(3-([1,1'-biphenyl]-4-yl)propyl)-4-butoxybenzenesulfonamide
[0342]
[0343] 4-Butoxybenzenesulfonyl chloride (40 μl, 0.200 mmol) was dissolved in dichloromethane (1 ml), 3-([1,1'-biphenyl]-4-yl)propane-1-amine (127 mg, 0.601 mmol) synthesized in step 3 above was added thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (14.4 mg, 16%, white solid).
[0344] The compounds of Examples 2 to 7 were prepared in a manner similar to that described in Step 4 of Example 1.
[0345] <Example 8> Preparation of 4-(2-(4-butoxybenzenesulfonylamino)ethyl)benzoic acid
[0346]
[0347] Step 1: Preparation of methyl 4-(2-((4-butoxyphenyl)sulfonamido)ethyl)benzoate
[0348]
[0349] In a similar manner to Example 1, Step 4, the target compound (6.7 mg, 28%, white solid) was obtained.
[0350] Step 2: Preparation of 4-(2-(4-butoxybenzenesulfonamido)ethyl)benzoic acid
[0351]
[0352] The compound 4-(2-((4-butoxyphenyl)sulfonamido)ethyl)benzoic acid methyl ester (23mg, 0.059mmol) prepared in the above step 1 was dissolved in methanol (0.5ml), 4M potassium hydroxide aqueous solution (0.147ml, 0.588mmol) was added dropwise thereto, and then stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was neutralized with 1M HCl aqueous solution. The reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (3.4g, 15%, white solid).
[0353] The compound of Example 9 was prepared by the same procedure as described in Example 8, Step 1.
[0354] <Example 10> Preparation of N-(2-(4-benzylpiperidin-1-yl)ethyl)-4-butoxybenzenesulfonamide
[0355]
[0356] Step 1: Preparation of tert-butyl (2-(4-benzylpiperidin-1-yl)ethyl)carbamate
[0357]
[0358] 4-Benzylpiperidine (8g, 45.6mmol) and potassium carbonate (K2CO3) (9.46g, 68.5mmol) were dissolved in DMF (228ml) and stirred at room temperature for 5 minutes. Tert-butyl (2-bromoethyl)carbamate (12.27g, 54.8mmol) was added dropwise to the reaction mixture and then stirred at 60°C for 12 hours. Tert-butyl (2-bromoethyl)carbamate (12.27g, 54.8mmol) was added dropwise to the reaction product again and then stirred at 60°C for 12 hours. After the reaction was completed, 1M HCl aqueous solution was added dropwise and extracted with dichloromethane. The organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain tert-butyl (2-(4-benzylpiperidin-1-yl)ethyl)carbamate (12.9g, 89%, white solid).
[0359] Step 2: Preparation of 2-(4-benzylpiperidin-1-yl)ethylamine 2HCl salt
[0360]
[0361] The tert-butyl (2-(4-benzylpiperidin-1-yl)ethyl)carbamate (12.9 g, 40.5 mmol) prepared in step 1 above was directly treated with 4M HCl in dioxane (10.13 ml, 40.5 mmol) and stirred at room temperature for 2 hours. After the reaction was complete, excess HCl was removed under reduced pressure. As a result, 2-(4-benzylpiperidin-1-yl)ethylamine 2HCl salt (8.9 g, 75%, white solid) was obtained.
[0362] Step 3: Preparation of N-(2-(4-benzylpiperidin-1-yl)ethyl)-4-butoxybenzenesulfonamide
[0363]
[0364] Using the compound prepared in step 2 above, the target compound (7.6 mg, 14%, clear oil) was obtained in a manner similar to that described in step 4 of example 1.
[0365] The compound of Example 11 was prepared in a manner similar to that described in Example 1, Step 4.
[0366] <Example 12> Preparation of 4-butoxy-N-(3-oxo-3-phenylpropyl)benzenesulfonamide
[0367]
[0368] Step 1: Preparation of (4-butoxy-N-(3-hydroxy-3-phenylpropyl)benzenesulfonamide
[0369]
[0370] The target compound was obtained in a similar manner to that described in Example 1, Step 4.
[0371] Step 2: Preparation of 4-butoxy-N-(3-oxo-3-phenylpropyl)benzenesulfonamide
[0372]
[0373] The compound prepared in step 1 above (30 mg, 0.121 mmol) was dissolved in dichloromethane (0.5 ml), and manganese (IV) oxide (31.1 mg, 0.358 mmol) was added dropwise thereto, and then stirred at room temperature for 12 hours. After the reaction was completed, the reaction mixture was filtered through diatomaceous earth, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (9.2 mg, 71%, white solid).
[0374] The compound of Example 13 was prepared in a manner analogous to the method described in Step 4 of Example 1.
[0375] <Example 14> Preparation of 4-(3-(dimethylamino)propoxy)-N-phenethylbenzenesulfonamide
[0376]
[0377] Step 1: Preparation of N,N-dimethyl-3-phenoxypropane-1-amine
[0378]
[0379] At 0°C, phenol (600 mg, 6.38 mmol), 3-(dimethylamino)propane-1-ol (0.88 ml, 7.44 mmol) and triphenylphosphine (2.508 g, 9.56 mmol) were dissolved in tetrahydrofuran (12 ml), diethyl azodicarboxylate solution (DEAD) (4.34 ml, 9.56 mmol) was added dropwise thereto, and then stirred at room temperature for 12 hours in a nitrogen atmosphere. After the reaction was completed, the solvent was removed under reduced pressure. The reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain N, N-dimethyl-3-phenoxypropane-1-amine (922 mg, 81%, yellow oil).
[0380] Step 2: Preparation of 4-(3-(dimethylamino)propoxy)benzene-1-sulfonyl chloride
[0381]
[0382] The N, N-dimethyl-3-phenoxypropane-1-amine (922mg, 5.14mmol) prepared in step 1 above was dissolved in dichloromethane (6ml), chlorosulfonic acid (1.37ml, 20.57mmol) was added dropwise thereto, and then stirred at room temperature for 3 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. As a result, 4-(3-(dimethylamino) propoxy)benzene-1-sulfonyl chloride (451mg, 32%, yellow solid) was obtained without further purification.
[0383] Step 3: Preparation of 4-(3-(dimethylamino)propoxy)-N-phenylethylbenzenesulfonamide
[0384]
[0385] 4-(3-(dimethylamino)propoxy)benzene-1-sulfonyl chloride (100 mg, 0.318 mmol) prepared in step 2 above was dissolved in dichloromethane (2 ml), 2-phenylethylamine (116 mg, 0.955 mmol) and potassium carbonate (K2CO3) (48.4 mg, 0.35 mmol) were added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (88 mg, 75%, transparent oil).
[0386] The compounds of Examples 15 and 16 were prepared in a manner analogous to the method described in Step 3 of Example 14.
[0387] <Example 17> Preparation of 4-(2-(4-(3-(dimethylamino)propoxy)benzenesulfonamido)ethyl)benzoic acid
[0388]
[0389] Step 1: Preparation of methyl 4-(2-(4-(3-(dimethylamino)propoxy)benzenesulfonamido)ethyl)benzoate
[0390]
[0391] The title compound was prepared by a procedure similar to Example 14, Step 3.
[0392] Step 2: Preparation of 4-(2-(4-(3-(dimethylamino)propoxybenzenesulfonamido)ethyl)benzoic acid
[0393]
[0394] The compound prepared in step 1 above (58 mg, 0.138 mmol) was dissolved in methanol (1 ml), and a 4M potassium hydroxide aqueous solution (0.69 ml, 2.76 mmol) was added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was neutralized with a 1M HCl aqueous solution, extracted with dichloromethane, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by preparative TLC to obtain the target compound (1.7 mg, 3%, white solid).
[0395] The compound of Example 18 was prepared in a manner analogous to the method described in Step 3 of Example 14.
[0396] <Example 19> Preparation of 4-butoxy-N-(3-(naphthalen-1-yl)propyl)benzenesulfonamide
[0397]
[0398] Step 1: Preparation of tert-butyl (3-(naphthalen-1-yl)propyl)carbamate
[0399]
[0400] Allyl carbamic acid tert-butyl ester (1g, 6.36mmol) is dissolved in tetrahydrofuran (6ml), 9-BBN (10mmol) dissolved in 0.5M tetrahydrofuran is added dropwise thereto, and stirred at room temperature for 2.5 hours. 1-iodonaphthalene (0.925ml, 6.36mmol), PdCl2(dppf)-CH2Cl2 (308mg, 0.377mmol) and 1M sodium hydroxide aqueous solution (10ml) are added dropwise to the reaction mixture, and then stirred at room temperature for 3 hours. PdCl2(dppf)-CH2Cl2 (55mg, 0.07mmol) is added dropwise thereto, and then stirred at room temperature for 14 hours. After the reaction is completed, saturated ammonium chloride aqueous solution is added dropwise thereto, and the reaction mixture is extracted with ethyl acetate, dried over magnesium sulfate, and the solvent is removed under reduced pressure. Then, the compound (1.6 g) obtained by separating and purifying the reaction mixture by MPLC was added dropwise to a mixture of tetrahydrofuran (20 ml), 15% aqueous sodium hydroxide solution (5 ml) and 30% hydrogen peroxide (10 ml) at 0°C, and then stirred at the same temperature for 2 hours. After the reaction was completed, ethyl acetate was added dropwise thereto, washed with a supersaturated aqueous sodium bicarbonate solution and brine, dried over anhydrous magnesium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain tert-butyl (3-(naphthalene-1-yl)propyl)carbamate (1.4 g, 77%).
[0401] Step 2: Preparation of 3-(naphthalen-1-yl)propan-1-amine
[0402]
[0403] The (3-(naphthalene-1-yl) propyl) tert-butyl carbamate (1.4g, 4.9mmol) prepared in the above steps 1 was dissolved in dichloromethane (20ml), trifluoroacetic acid (10ml, 130mmol) was added dropwise thereto, and then stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was neutralized by dropping 10% sodium hydroxide aqueous solution. The reaction mixture was extracted with dichloromethane, the organic layer was washed with water and salt water successively, anhydrous sodium sulfate drying was used, and the solvent was removed under reduced pressure to obtain 3-(naphthalene-1-yl) propane-1-amine (925mg, 100%).
[0404] Step 3: Preparation of 4-butoxy-N-(3-(naphthalen-1-yl)propyl)benzenesulfonamide
[0405]
[0406] Using the compound prepared in step 2 above, the target compound (66 mg, 82%, transparent solid) was obtained in a similar manner to step 4 of example 1.
[0407] The compound of Example 20 was prepared in a manner similar to that described in Example 1, Step 4.
[0408] <Example 21> Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)benzenesulfonamide
[0409]
[0410] Step 1: Preparation of N,N-dimethyl-2-phenoxyethane-1-amine
[0411]
[0412] At 0°C, phenol (500mg, 5.31mmol), 2-(dimethylamino)ethane-1-ol (521mg, 5.84mmol) and triphenylphosphine (2.089g, 797mmol) were dissolved in tetrahydrofuran (20ml), diethyl azodicarboxylate solution (DEAD) (3.61ml, 7.97mmol) was added dropwise thereto, and then stirred at room temperature for 12 hours in a nitrogen atmosphere. After the reaction was completed, the solvent was removed under reduced pressure. The reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain N,N-dimethyl-2-phenoxyethane-1-amine (870mg, 99%, yellow solid).
[0413] Step 2: Preparation of 4-(2-(dimethylamino)ethoxy)benzenesulfonyl chloride
[0414]
[0415] The N, N-dimethyl-3-phenoxyethane-1-amine (533mg, 3.23mmol) prepared in step 1 above was dissolved in dichloromethane (3ml), chlorosulfonic acid (0.858ml, 12.90mmol) was added dropwise thereto at 0°C, and then stirred at room temperature for 3 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. As a result, 4-(2-(dimethylamino)ethoxy)benzenesulfonyl chloride (622mg, 73%, yellow oil) was obtained without further purification.
[0416] Step 3: Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(2-(dimethylamino)ethoxy)benzenesulfonamide
[0417]
[0418] 4-(2-(dimethylamino)ethoxy)benzenesulfonyl chloride (45 mg, 0.171 mmol) prepared in step 2 above was dissolved in dichloromethane, 3-(1H-indol-3-yl)propane-1-amine (131 mg, 0.751 mmol) was added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (11 mg, 17%, yellow solid).
[0419] The compound of Example 22 was prepared in a manner analogous to the method described in Example 14.
[0420] The compounds of Examples 23 to 25 were prepared in a manner analogous to the method described in Example 1, Step 4.
[0421] <Example 26> Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(isopentyloxy)benzenesulfonamide
[0422]
[0423] 4-(Isopentyloxy)benzenesulfonyl chloride (20 mg, 0.076 mmol) was dissolved in dichloromethane (1.5 ml), 3-(1H-indol-3-yl)propane-1-amine (30 mg, 0.172 mmol) was added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (26 mg, 85%, yellow solid).
[0424] <Example 27> Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(pentyloxy)benzenesulfonamide
[0425]
[0426] 4-(Pentyloxy)benzenesulfonyl chloride (20 mg, 0.076 mmol) was dissolved in dichloromethane, 3-(1H-indol-3-yl)propane-1-amine (30 mg, 0.172 mmol) was added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (25 mg, 81%, white solid).
[0427] The compound of Example 28 was prepared in a manner analogous to the method described in Step 4 of Example 1.
[0428] <Example 29> Preparation of 4-butoxy-N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)benzenesulfonamide
[0429]
[0430] 4-Butoxybenzenesulfonyl chloride (50 mg, 0.201 mmol) was dissolved in dichloromethane (1 ml), 3-(2-aminoethyl)-1H-indol-5-ol hydrochloride (128 mg, 0.603 mmol) and triethylamine (0.084 ml, 0.603 mmol) were added dropwise thereto, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (10.2 mg, 13%, white solid).
[0431] <Example 30> Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(3-morpholinopropoxy)benzenesulfonamide
[0432]
[0433] Step 1: Preparation of 4-(3-phenoxypropyl)morpholine
[0434]
[0435] At 0°C, phenol (600mg, 6.38mmol), 4-(3-hydroxypropyl)morpholine (1.11g, 7.65mmol) and triphenylphosphine (2.5g, 9.56mmol) were dissolved in tetrahydrofuran (16ml), diethyl azodicarboxylate solution (DEAD) (4.34ml, 9.56mmol) was added dropwise thereto, and then stirred at room temperature for 12 hours in a nitrogen atmosphere. After the reaction was completed, the solvent was removed under reduced pressure. The reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain 4-(3-phenoxypropyl)morpholine (1.41g, 100%, transparent oil).
[0436] Step 2: Preparation of 4-(3-morpholinopropoxy)benzene-1-sulfonyl chloride
[0437]
[0438] The 4-(3-phenoxypropyl)morpholine (1.41 g, 6.38 mmol) prepared in the above step 1 was dissolved in dichloromethane (12 ml), chlorosulfonic acid (1.69 ml, 25.5 mmol) was added thereto at 0°C, and then stirred at room temperature for 3 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. As a result, 4-(3-morpholinopropoxy)benzene-1-sulfonyl chloride (2.22 g, 67%, yellow solid) was obtained without further purification.
[0439] Step 3: Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(3-morpholinopropoxy)benzenesulfonamide
[0440]
[0441] The 4-(3-morpholinopropoxy)benzene-1-sulfonyl chloride (150 mg, 0.469 mmol) prepared in the above step 2 was dissolved in dichloromethane (1.5 ml), 3-(1H-indol-3-yl)propane-1-amine (245 mg, 1.407 mmol) and potassium carbonate (194 mg, 1.407 mmol) were added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (10.6 mg, 5%, yellow solid).
[0442] <Example 31> Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0443]
[0444] Step 1: Preparation of 4-(3-bromopropoxy)benzene-1-sulfonyl chloride
[0445]
[0446] (3-bromopropoxy)benzene (1g, 4.65mmol) was dissolved in dichloromethane (15ml), chlorosulfonic acid (1.236ml, 18.60mmol) was added dropwise thereto at 0°C, and then stirred at room temperature for 1 hour. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. As a result, 4-(3-bromopropoxy)benzene-1-sulfonyl chloride (1.1g, 38%, yellow solid) was obtained without further purification.
[0447] Step 2: Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(3-bromopropoxy)benzenesulfonamide
[0448]
[0449] 4-(3-bromopropoxy)benzene-1-sulfonyl chloride (538mg, 1.716mmol) prepared in the above step 1 was dissolved in dichloromethane (5ml), 3-(1H-indol-3-yl)propane-1-amine (897mg, 5.15mmol) and potassium carbonate (K2CO3) (711mg, 5.15mmol) were added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain N-(3-(1H-indol-3-yl)propyl)-4-(3-bromopropoxy)benzenesulfonamide (230mg, 29%, white solid).
[0450] Step 3: N-(3-(1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide Preparation
[0451]
[0452] N-(3-(1H-indol-3-yl)propyl)-4-(3-bromopropoxy)benzenesulfonamide (175 mg, 0.388 mmol) prepared in the above step 2 was dissolved in ethanol (1.5 ml), 1-methylpiperazine (0.172 ml, 1.551 mmol) and potassium carbonate (K2CO3) (80 mg, 0.582 mmol) were added dropwise thereto, and then stirred at 70°C for 12 hours. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (66 mg, 36%, white solid).
[0453] The compounds of Examples 23 to 25 were prepared in a manner similar to that described in Example 1, Step 4.
[0454] The compounds of Examples 34 and 35 were prepared in a manner similar to that described in Example 30.
[0455] The compound of Example 36 was prepared in analogy to the method described in Example 31.
[0456] The compounds of Examples 37 to 40 were prepared in analogy to the method described in Example 14.
[0457] The compounds of Examples 41 and 42 were prepared in a manner similar to that described in Example 30.
[0458] The compounds of Examples 43 to 45 were prepared in analogy to the method described in Example 31.
[0459] <Example 46> Preparation of 4-(3-(dimethylamino)propoxy)-N-(3-(1-methyl-1H-indol-3-yl)propyl)benzenesulfonamide
[0460]
[0461] Step 1: Preparation of N-(3-(1H-indol-3-yl)propyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide
[0462] N-(3-(1H-Indol-3-yl)propyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide was prepared in a manner similar to that described in Example 14.
[0463] Step 2: 4-(3-(dimethylamino)propoxy)-N-(3-(1-methyl-1H-indol-3-yl)propyl)benzenesulfonyl Preparation of amines
[0464]
[0465] N-(3-(1H-indol-3-yl)propyl)-4-(3-(dimethylamino)propoxy)benzenesulfonamide (150mg, 0.981mmol) prepared in the above step 1 was dissolved in DMF (1ml), and sodium hydride (60%) (51.5mg, 1.287mmol) was added dropwise thereto at -20°C, followed by stirring for 30 minutes. Iodomethane (23μl, 0.368mmol) dissolved in DMF (0.1ml) was slowly added dropwise thereto at the same temperature, and then stirred at room temperature for 12 hours. After completion of the reaction, the reaction mixture was extracted with ethyl acetate and neutralized with a supersaturated aqueous ammonium chloride solution. The organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (13.7mg, 8%, clear oil).
[0466] <Example 47> Preparation of N-(3-(1H-indol-3-yl)propyl)-4-bromobenzenesulfonamide
[0467]
[0468] Step 1: Preparation of 4-bromobenzene-1-sulfonyl chloride
[0469]
[0470] Bromobenzene (0.067 ml, 0.637 mmol) was dissolved in dichloromethane (2 ml), chlorosulfonic acid (0.169 ml, 2.55 mmol) was added dropwise thereto at 0°C, and then stirred at room temperature for 3 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. As a result, 4-bromobenzene-1-sulfonyl chloride (74 mg, 45%, white solid) was obtained without further purification.
[0471] Step 2: Preparation of N-(3-(1H-indol-3-yl)propyl)-4-bromobenzenesulfonamide
[0472]
[0473] The 4-bromobenzene-1-sulfonyl chloride (74 mg, 0.29 mmol) prepared in the above step 1 was dissolved in dichloromethane (1 ml), 3-(1H-indol-3-yl)propane-1-amine (151 mg, 0.869 mmol) and potassium carbonate (K2CO3) (120 mg, 0.869 mmol) were added dropwise thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane, and the organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (71 mg, 62%, white solid).
[0474] The compounds of Examples 48 to 54 were prepared in analogy to the method described in Example 31.
[0475] The compound of Example 55 was prepared in a manner similar to that described in Example 30.
[0476] The compounds of Examples 56 to 58 were prepared in analogy to the method described in Example 31.
[0477] The compounds of Examples 59 and 60 were prepared in analogy to the method described in Example 30.
[0478] Example 61 The compound was prepared in a manner similar to that described in Example 31.
[0479] Example 62 The compound was prepared in a manner similar to that described in Example 30.
[0480] The compounds of Examples 63 to 71 were prepared in analogy to the method described in Example 31.
[0481] <Example 72> Preparation of 4-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propoxy)-N-(3-(5-fluoro-1H-indol-3-yl)propyl)benzenesulfonamide
[0482]
[0483] Step 1: (2S,6R)-4-(3-(4-(N-(3-(5-fluoro-1H-indol-3-yl)propyl)sulfamoyl)phenoxy) Preparation of tert-butyl (propyl)-2,6-dimethylpiperazine-1-carboxylate
[0484] (2S,6R)-tert-Butyl 4-(3-(4-(N-(3-(5-fluoro-1H-indol-3-yl)propyl)sulfamoyl)phenoxy)propyl)-2,6-dimethylpiperazine-1-carboxylate was prepared in a manner similar to that described in Example 31.
[0485] Step 2: 4-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propoxy)-N-(3-(5-fluoro-1H-indole-3-yl)propoxy)- Preparation of 1-(2-propyl)benzenesulfonamide
[0486]
[0487] The (2S, 6R)-4-(3-(4-(N-(3-(5-fluoro-1H-indol-3-yl)propyl)sulfamoyl)phenoxy)propyl)-2,6-dimethylpiperazine-1-carboxylic acid tert-butyl ester (80 mg, 0.133 mmol) prepared in the above step 1 was dissolved in dichloromethane (1 ml), trifluoroacetic acid (0.2 ml, 2.65 mmol) was added at room temperature, and then stirred at room temperature for 3 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with ethyl acetate and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (5.2 mg, 7%, white solid).
[0488] The compounds of Examples 73 to 76 were prepared in analogy to the method described in Example 31.
[0489] <Example 77> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-(methylamino)azetidin-1-yl)propoxy)benzenesulfonamide
[0490]
[0491] Step 1: (1-(3-(4-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)phenoxy)propyl)nitrogen Preparation of tert-butyl (3-heterocyclobutane) (methyl) carbamate
[0492] Tert-butyl (1-(3-(4-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)phenoxy)propyl)azetidin-3-yl(methyl)carbamate was prepared in a manner analogous to that described in Example 31.
[0493] Step 2: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-(methylamino)azetidine-1-yl)- Preparation of (4-(2-propyl)propoxy)benzenesulfonamide
[0494]
[0495] Using the azetidin-3-yl (methyl) carbamic acid tert-butyl ester prepared in the above step 1, (1- (3- (4- (N- (3- (5- chloro-1H- indol-3-yl) propyl) sulfamoyl) phenoxy) propyl) azetidin-3-yl) (methyl) tert-butyl carbamate (38mg, 0.064mmol) was dissolved in dichloromethane (0.5ml), trifluoroacetic acid (0.2ml, 2.61mmol) was added dropwise thereto at room temperature, and then stirred at room temperature for 2 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with ethyl acetate and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by MPLC to obtain the target compound (7mg, 22%, yellow solid).
[0496] The compound of Example 78 was prepared in a manner similar to that described in Example 31.
[0497] <Example 79> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-6-(3-(piperazin-1-yl)propoxy)pyridine-3-sulfonamide
[0498]
[0499] Step 1: Preparation of tert-butyl 4-(3-((5-bromopyridin-2-yl)oxy)propylpiperazine-1-carboxylate
[0500]
[0501] 5-bromo-2-fluoropyridine (0.326ml, 2.84mmol) is dissolved in DMF (12ml), 60%wt sodium hydride (0.159g, 3.98mmol) is added dropwise thereto at 0°C, and then stirred for 5 minutes. 4-(3-hydroxypropyl) piperazine-1-carboxylic acid tert-butyl ester is added dropwise thereto, and stirred for 6 hours at 70°C. After the reaction is completed, ice is added thereto. The reaction mixture is extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer is washed with water and brine in turn, dried over anhydrous sodium sulfate, and the solvent is removed under reduced pressure. As a result, 4-(3-((5-bromopyridine-2-yl)oxy)propylpiperazine-1-carboxylic acid tert-butyl ester (1.35g, 110%) is obtained without further purification.
[0502] Step 2: tert-4-(3-((5-((4-methoxybenzyl)thio)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylic acid Preparation of Butyl Ester
[0503]
[0504] 4-(3-((5-bromopyridin-2-yl)oxy)propylpiperazine-1-carboxylic acid tert-butyl ester (0.52 g, 1.3 mmol) prepared in step 1 was dissolved in 1.4-dioxane (12 ml), and (4-methoxyphenyl)methanethiol (0.199 ml, 1.23 mmol) and N-ethyl-N-isopropylpropane-2-amine (0.681 ml, 3.90 mmol) were added dropwise thereto, and then reacted in a nitrogen atmosphere for 5 minutes, and Pd2(dba)3 (9.91 mg, 0.032 mmol), Xa ntphos (0.038 g, 0.065 mmol) and tert-butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate were then reacted in a Biotage microwave at 150 ° C for 30 minutes. After the reaction was completed, the reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution, the organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. As a result, tert-butyl 4-((5-methoxy)propyl)piperazine-1-carboxylate (51 g) was obtained, and tert-butyl 3-((5-methoxybenzyl)formate was obtained without further purification.
[0505] Step 3: Preparation of tert-butyl 4-(3-((5-(chlorosulfonyl)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylate
[0506]
[0507] The tert-butyl 4-(3-((5-((4-methoxybenzyl)thio)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylate (0.469 g, 0.99 mmol) prepared in the above step 2 was dissolved in acetic acid (8 ml) and water (2 ml), N-chlorosuccinimide (0.529 g, 3.96 mmol) was added dropwise thereto, and then reacted at room temperature for 1 hour. After the reaction was completed, the reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. As a result, tert-butyl 4-(3-((5-(chlorosulfonyl)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylate (0.25 g, 60%) was obtained without further purification.
[0508] Step 4: 4-(3-((5-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)pyridin-2-yl)oxy) Preparation of tert-butyl (propyl) piperazine-1-carboxylate
[0509]
[0510] The tert-butyl 4-(3-((5-(chlorosulfonyl)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylate (0.1 g, 0.238 mmol) prepared in the above step 3 was dissolved in DMF (2 ml), 3-(5-chloro-1H-indol-3-yl)propane-1-amine (0.055 g, 0.262 mmol) and potassium carbonate (0.066 g, 0.476 mmol) were added dropwise thereto, and then stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was extracted with dichloromethane and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in turn, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by preparative TLC to give tert-butyl 4-(3-((5-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylate (18 mg, 12.8%).
[0511] Step 5: N-(3-(5-chloro-1H-indol-3-yl)propyl)-6-(3-(piperazin-1-yl)propoxy)pyridine-3-sulfonyl Preparation of amides
[0512]
[0513] 4-(3-((5-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)pyridin-2-yl)oxy)propyl)piperazine-1-carboxylate (18 mg, 0.034 mmol) prepared in the above step 4 was dissolved in tetrahydrofuran (1 ml), trifluoroacetic acid (0.5 ml, 6.49 mmol) was added dropwise thereto at room temperature, and then stirred at room temperature for 2 hours. After the reaction was completed, ice was added thereto. The reaction mixture was extracted with ethyl acetate and neutralized with a supersaturated aqueous sodium carbonate solution. The organic layer was washed with water and brine in sequence, dried over anhydrous sodium sulfate, and then the solvent was removed under reduced pressure. Then, the reaction mixture was separated and purified by preparative TLC to obtain the target compound (4.5 mg, 30%).
[0514] The compounds of Examples 80 to 84 were prepared in analogy to the method described in Example 31.
[0515] <Example 85> Preparation of N-(3-(1H-indol-3-yl)cyclohexyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0516]
[0517] Step 1: Preparation of 3-(1H-indol-3-yl)cyclohexane-1-one
[0518]
[0519] 1H-indole (1 g, 8.54 mmol) and cyclohex-2-enone (1.64 g, 17.1 mmol) were dissolved in CH3CN (30 ml), Sc(OTf)3 (0.42 g, 0.854 mmol) was added, and the mixture was stirred at 30°C for 3 hours in a N2 atmosphere. After the reaction was completed, the reaction solution was concentrated under reduced pressure and purified by preparative HPLC to obtain the target compound (805 mg, 44%).
[0520] Step 2: Preparation of 3-(1H-indol-3-yl)cyclohexane-1-amine
[0521]
[0522] 3-(1H-indol-3-yl)cyclohexane-1-one (800mg, 3.75mmol) prepared in the above step 1 was dissolved in dichloroethane (10ml) and acetic acid (0.5ml), and ammonium acetate (8.67g, 113mmol) was added thereto at room temperature, followed by stirring for 2 hours. Then, sodium triacetoxyborohydride (3.18g, 15.0mmol) was added at room temperature, followed by stirring for 5 hours. After the reaction was completed, the reaction mixture obtained by concentrating the mixture under reduced pressure was separated and purified by MPLC to obtain the target compound (250mg, 31%, yellow solid).
[0523] Step 3: Preparation of N-(3-(1H-indol-3-yl)cyclohexyl)-4-(3-bromopropoxy)benzenesulfonamide
[0524]
[0525] The title compound (100 mg, 46%, white solid) was obtained by following a procedure similar to that described in step 2 of Example 31 using 3-(1H-indol-3-yl)cyclohexane-1-amine (105 mg, 0.491 mmol) prepared in step 2 above and 4-(3-bromopropoxy)benzenesulfonyl chloride (140 mg, 0.446 mmol) obtained by following a procedure similar to that described in step 2 of Example 31.
[0526] Step 4: N-(3-(1H-indol-3-yl)cyclohexyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonyl Preparation of amines
[0527]
[0528] Using N-(3-(1H-indol-3-yl)cyclohexyl)-4-(3-bromopropoxy)benzenesulfonamide (30 mg, 0.061 mmol) and 1-methylpiperazine (24.5 mg, 0.244 mmol) obtained in the above step 3, the target compound (21.6 mg, 69% yield) was obtained as a white solid in a manner similar to the method described in step 3 of Example 31.
[0529] <Example 86> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)naphthalene-1-sulfonamide
[0530]
[0531] Step 1: Preparation of 4-(3-bromopropoxy)naphthalene-1-sulfonic acid sodium salt (I)
[0532]
[0533] 4-Hydroxynaphthalene-1-sulfonic acid sodium salt (I) (0.3 g, 1.218 mmol) was dissolved in ethanol (2.5 ml), 1,3-dibromopropane (0.211 ml, 2.071 mmol), tetrabutylammonium sulfate (0.033 g, 0.097 mmol) and potassium hydroxide aqueous solution (1.56 ml, 1.218 mmol) were added thereto, and then heated under reflux for 3 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, dissolved in ethanol again, and concentrated again. After adding hot methanol to the reaction solution, the insoluble matter was filtered and the filtrate was concentrated. The obtained solid was washed with dichloromethane and filtered to obtain the target compound (0.4 g, 99%, white solid).
[0534] Step 2: Preparation of 4-(3-bromopropoxy)naphthalene-1-sulfonyl chloride
[0535]
[0536] Thionyl chloride (0.286 ml, 3.92 mmol) and dimethylformamide (1.91 μl) were added to the compound (0.2 g, 0.545 mmol) prepared in step 1 above, and then heated to reflux for 4 hours. After the reaction was completed, the temperature was lowered to room temperature, and the reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic layer residue was dried over anhydrous sodium sulfate, filtered and concentrated, and used in the next step without further purification.
[0537] Step 3: Preparation of 4-(3-bromopropoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)naphthalene-1-sulfonamide
[0538]
[0539] The title compound was prepared by a procedure similar to Example 31, Step 2.
[0540] Step 4: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)naphthalene- Preparation of 1-sulfonamide
[0541]
[0542] The title compound was prepared by a procedure similar to that of Example 31, Step 3.
[0543] The compound of Example 87 was prepared in analogy to the method described in Example 31.
[0544] <Example 88> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperidin-4-yl)propyl)amino)benzenesulfonamide
[0545]
[0546] Step 1: Preparation of tert-butyl 4-(3-oxopropyl)piperidine-1-carboxylate
[0547]
[0548] Tert-butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate (0.3 g, 1.233 mmol) was dissolved in dichloromethane (6 ml), to which Dess-Martin Periodiane (0.680 g, 1.603 mmol) was added at 0°C, and then stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was filtered, and the filtrate was washed with sodium bicarbonate aqueous solution and brine. The organic layer residue was dried over anhydrous sodium sulfate, filtered and concentrated. The concentrate was purified by MPLC to obtain the target compound (0.24 g, 79%, clear oil).
[0549] Step 2: Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-nitrobenzenesulfonamide
[0550]
[0551] The title compound was prepared by a procedure similar to Example 31, Step 2.
[0552] Step 3: Preparation of 4-amino-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide
[0553]
[0554] The compound prepared in step 2 above (0.72 g, 1.840 mmol) was dissolved in ethyl acetate (12 ml), and tin (II) chloride and dihydrate (4.15 g, 18.40 mmol) were added thereto, followed by heating at 60° C. for 5 hours. After the reaction was completed, aqueous ammonia was added to the reaction solution to adjust the pH to 5, sodium carbonate was added to adjust the pH to 7, the reaction solution was filtered through celite, the filtrate was concentrated under reduced pressure, and it was used in the next step without further purification.
[0555] Step 4: 4-(3-((4-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)phenyl)amino)propyl) Preparation of tert-butyl piperidine-1-carboxylate
[0556]
[0557] The compound prepared in step 3 above (0.05 g, 0.137 mmol) was dissolved in dichloroethane (1 ml), and the compound prepared in step 1 above (0.046 g, 0.192 mmol) and acetic acid (0.024 ml, 0.412 mmol) were added thereto, followed by stirring at room temperature for 1 hour. Sodium triacetoxyborohydride (0.087 g, 0.412 mmol) was added thereto, and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The organic layer residue was dried over anhydrous sodium sulfate, filtered and concentrated, purified by preparative HPLC, and added to an aqueous sodium bicarbonate solution to obtain the target compound (0.017 g, 5%, yellow solid).
[0558] Step 5: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperidin-4-yl)propyl)amino)benzenesulfonyl Preparation of amines
[0559]
[0560] The title compound was prepared in a manner similar to that described in Example 79, Step 5.
[0561] <Example 89> Preparation of N-(3-(1H-indol-3-yl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0562]
[0563] Step 1: Preparation of 3-(3-nitrophenyl)-1H-indole
[0564]
[0565] N-(2-ethynylphenyl)-2,2,2-trifluoroacetamide and 1-iodo-3-nitrobenzene were dissolved in DMSO and treated with excess K2CO3 in the presence of a catalytic amount of Pd2(dba)3 to obtain the target compound 3-(3-nitrophenyl-1H-indole).
[0566] Step 2: Preparation of 3-(1H-indol-3-yl)aniline
[0567]
[0568] The compound prepared in step 1 above (0.047 g, 0.197 mmol) was dissolved in methanol (2 ml), Pd / C (0.004 g, 3.76 μmol) was added thereto, and then stirred at room temperature for 3 hours in hydrogen. After the reaction was completed, the reaction solution was filtered through diatomaceous earth and washed with methanol. The filtrate was concentrated under reduced pressure and used directly in the next step without further purification.
[0569] Step 3: Preparation of N-(3-(1H-indol-3-yl)phenyl)-4-(3-bromopropoxy)benzenesulfonamide
[0570]
[0571] The compound prepared in step 2 above (0.041 g, 0.197 mmol) was dissolved in pyridine (1 ml), and the compound prepared in step 1 of Example 31 (0.068 g, 0.217 mmol) was added thereto at 0°C, followed by stirring at room temperature for 3 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and purified by MPLC to obtain the target compound (0.047 g, 49%, yellow solid).
[0572] Step 4: N-(3-(1H-indol-3-yl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide Preparation
[0573]
[0574] The title compound was prepared by a procedure similar to that of Example 31, Step 3.
[0575] <Example 90> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-1-yl)butyl)benzenesulfonamide
[0576]
[0577] Step 1: Preparation of 4-(4-bromobutyl)benzene-1-sulfonyl chloride
[0578]
[0579] Using a procedure analogous to that described in Step 1 of Example 31 using (4-bromobutyl)benzene (1.0 g, 4.69 mmol) and chlorosulfonic acid (0.936 ml, 14.1 mmol), the title compound (1.4 g, 96%, white solid) was prepared.
[0580] Step 2: Preparation of 4-(4-bromobutyl)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide
[0581]
[0582] The 4-(4-bromobutyl)benzene-1-sulfonyl chloride (300 mg, 0.963 mmol) prepared in the above step 1 was dissolved in dichloromethane (5 ml), and 3-(5-chloro-1H-indol-3-yl)propane-1-amine (211 mg, 1.01 mmol) and triethylamine (0.268 ml, 1.93 mmol) were added thereto at room temperature, and then stirred for 3 hours. After the reaction was completed, the mixture was concentrated under reduced pressure and purified by MPLC to obtain the target compound (330 mg, 71%, white solid).
[0583] Step 3: Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-1-yl)butyl)benzenesulfonamide Preparation
[0584]
[0585] Using a method similar to that described in Step 3 of Example 31, using 4-(4-bromobutyl)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide (30 mg, 0.062 mmol) prepared in Step 2 above, piperidine (15.9 mg, 0.186 mmol) and potassium carbonate (12.9 mg, 0.093 mmol), the title compound (16 mg, 53%) was obtained as a white solid.
[0586] The compound of Example 91 was prepared in a manner similar to that described in Example 90.
[0587] <Example 92> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonamide
[0588]
[0589] Step 1: Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-hydroxybenzenesulfonamide
[0590]
[0591] 4-Hydroxybenzene-1-sulfonyl chloride (0.5 g, 2.60 mmol) was dissolved in dichloromethane (8.7 ml), 3-(5-chloro-1H-indol-3-yl)propane-1-amine (0.596 g, 2.86 mmol) and triethylamine (0.724 ml, 5.19 mmol) were added thereto, and then stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (0.19 g, 21%, white solid).
[0592] Step 2: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonate Preparation of amides
[0593]
[0594] The compound prepared in step 1 above (0.05 g, 0.137 mmol) was dissolved in tetrahydrofuran (1.5 ml) at 0°C under nitrogen, 3-(1-methylpiperidin-4-yl)propane-1-ol (0.026 g, 0.164 mmol), PPh3 (0.054 g, 0.206 mmol) and DEAD (0.093 ml, 0.206 mmol) were added thereto, followed by stirring for 1 hour. After completion of the reaction, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, purified by preparative HPLC, and obtained as a white solid by adding sodium bicarbonate aqueous solution.
[0595] <Example 93> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-4-yl)propoxy)benzenesulfonamide
[0596]
[0597] The compound (0.035 g, 0.061 mmol) prepared in a manner similar to that described in Example 92 was dissolved in dichloromethane (2 ml), trifluoroacetic acid (1 ml, 12.98 mmol) was added thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure, purified by preparative HPLC, and added to a sodium bicarbonate aqueous solution to obtain the target compound (0.01 g, 37%, white solid).
[0598] The compound of Example 94 was prepared in a manner similar to that described in Example 93.
[0599] The compounds of Examples 95 and 96 were prepared in a manner similar to that described in Example 94.
[0600] The compound of Example 97 was prepared in analogy to the method described in Example 31.
[0601] <Example 98> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzenesulfonamide
[0602]
[0603] The compound (0.05 g, 0.136 mmol) prepared in a manner similar to that described in Step 2 of Example 47 was dissolved in dimethylformamide (1 ml), and 3-(4-methylpiperazin-1-yl)propan-1-amine (0.043 g, 0.273 mmol) and potassium carbonate (0.021 g, 0.150 mmol) were added thereto, followed by stirring at 100° C. for 3 days. After the reaction was completed, the reaction solution was concentrated under reduced pressure, purified by preparative HPLC, and neutralized by adding aqueous sodium bicarbonate solution to obtain the target compound (0.01 g, 16%, white solid).
[0604] <Example 99> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-4-yl)butyl)benzenesulfonamide
[0605]
[0606] Step 1: Preparation of 4-(but-3-en-1-yl)piperidin-1-methyl tert-butyl ester
[0607]
[0608] Methyltriphenylphosphonium bromide (1.184 g, 3.32 mmol) was dissolved in anhydrous tetrahydrofuran (2 ml), and lithium bistrimethylsilylamide (3.32 ml, 3.32 mmol) was slowly added thereto at 0°C. Tert-butyl 4-(3-oxopropyl)piperidine-1-carboxylate (0.4 g, 1.66 mmol) prepared in step 1 of Example 88 was dissolved in anhydrous tetrahydrofuran (2 ml) and slowly added dropwise at 0°C. The mixture was stirred at 0°C for 30 minutes and then at room temperature for 20 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, washed with brine, and extracted with ethyl acetate. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by MPLC to obtain the target compound (0.2 g, 50%, clear oil).
[0609] Step 2: 4-(4-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)phenyl)butyl)piperidin-1-carboxylate Preparation of tert-butyl ester
[0610]
[0611] The tert-butyl 4-(but-3-ene-1-yl)piperidine-1-carboxylate (50 mg, 0.209 mmol) prepared in step 2 above was dissolved in anhydrous tetrahydrofuran (1.5 ml), and 9-borabicyclo[3.3.1]nonane (0.796 ml, 0.398 mmol) was added thereto at room temperature. The reaction mixture was gradually heated and stirred under reflux for 1 hour. After the reaction was completed, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The obtained residue was dissolved in 1,4-dioxane (1.5 ml), and 4-bromo-N-(3-(5-chloro-1H-indol-3)-yl)propyl)benzenesulfonamide (85 mg, 0.199 mmol) and 1M aqueous sodium carbonate solution (0.597 ml, 0.597 mmol) prepared in a manner similar to that of step 2 of Example 90 were added thereto. Pd(PPh3)4 (23 mg, 0.02 mmol) was added to the reaction mixture, and the mixture was gradually heated and stirred at 90°C for 3 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, filtered through celite, concentrated under reduced pressure, and purified by preparative HPLC to obtain the target compound (15 mg, 13%, yellow solid).
[0612] Step 3: Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-4-yl)butyl)benzenesulfonamide Preparation
[0613]
[0614] Tert-butyl 4-(4-(4-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)phenyl)piperidine-1-carboxylate (15 mg, 0.013 mmol) prepared in the above step 2 was dissolved in dichloromethane (2 ml), trifluoroacetic acid (1 ml, 13.1 mmol) was added thereto at room temperature, and then stirred for 1 hour. After the reaction was completed, the residue obtained by concentrating the mixture was washed with a supersaturated aqueous sodium bicarbonate solution and then extracted with ethyl acetate. The extracted organic layer was washed with distilled water, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to obtain the target compound (5 mg, 56%, white solid).
[0615] The compounds of Examples 100 to 102 were prepared in analogy to the method described in Example 31.
[0616] <Example 103> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0617]
[0618] Step 1: Preparation of 1-(3-bromopropoxy)-2-fluorobenzene
[0619]
[0620] 2-Fluorophenol (5 g, 44.6 mmol) was dissolved in acetonitrile (74 ml), 1,3-dibromopropane (90 g, 446 mmol) and potassium carbonate (6.16 g, 44.6 mmol) were added thereto, and then stirred at 80° C. for 16 hours. After the reaction was completed, the reaction solution was filtered, concentrated under reduced pressure, and used in the next step without further purification.
[0621] Step 2: Preparation of 4-(3-bromopropoxy)-3-fluorobenzenesulfonyl chloride
[0622]
[0623] The compound prepared in step 1 above (5 g, 19.31 mmol) was dissolved in dichloromethane (38 ml), chlorosulfonic acid (5.13 ml, 77 mmol) was added thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was diluted with dichloromethane and neutralized with aqueous sodium carbonate at 0°C. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and used in the next step without further purification.
[0624] Step 3: Preparation of 4-(3-bromopropoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluorobenzenesulfonamide
[0625]
[0626] The compound prepared in step 2 above (1 g, 3.02 mmol) was dissolved in dichloromethane (6 ml), 3-(5-chloro-1H-indol-3-yl)propane-1-amine (0.818 g, 3.92 mmol) and potassium carbonate (0.542 g, 3.92 mmol) were added thereto, and then stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (1.1 g, 77%, white solid).
[0627] Step 4: N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-methylpiperazin-1-yl)propoxy Preparation of 2-(4-(2-aminophenyl)benzenesulfonamide
[0628]
[0629] The compound prepared in step 3 above (0.05 g, 0.099 mmol) was dissolved in ethanol (1 ml), potassium carbonate (0.021 g, 0.149 mmol) and 1-methylpiperazine (0.020 g, 0.198 mmol) were added thereto, and then stirred at 70 ° C for 16 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, purified by preparative HPLC, and then neutralized by adding sodium bicarbonate aqueous solution to obtain the target compound (0.011 g, 22%, white solid).
[0630] The compounds of Examples 104 to 106 were prepared in analogy to the method described in Example 103.
[0631] <Example 107> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0632]
[0633]
[0634] By a procedure similar to that described in Step 4 of Example 99, using tert-butyl 4-(3-(4-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)phenoxy)propyl)-2-methylpiperazine-1-carboxylate (25 mg, 0.041 mmol) and trifluoroacetic acid (1 ml, 13.1 mmol) obtained by a procedure similar to that described in Example 31, the title compound (15 mg, 72%) was obtained as a light yellow solid.
[0635] The compounds of Examples 108 to 111 were prepared in a manner analogous to the method described in Example 107.
[0636] Example 112 was prepared in a manner analogous to that described in Example 90.
[0637] <Example 113> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperazin-1-yl)propyl)amino)benzenesulfonamide
[0638]
[0639] The compound (0.0142 g, 0.024 mmol) prepared in a manner similar to that described in Example 98 was dissolved in dichloromethane (2 ml), trifluoroacetic acid (1 ml, 12.98 mmol) was added thereto, and then stirred at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure, purified by preparative HPLC, and neutralized by adding aqueous sodium bicarbonate solution to obtain the target compound (0.005 g, 50%, white solid).
[0640] Example 114 was prepared in a similar manner to Example 98.
[0641] The compound of Example 115 was prepared in a similar manner to that in Steps 1 to 3 of Example 99.
[0642] <Example 116> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((1-((4-methylpiperazin-1-yl)methyl)cyclopropyl)methoxy)benzenesulfonamide
[0643]
[0644] Step 1: Preparation of (1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)methanol
[0645]
[0646] Cyclopropane-1,1-dimethanol (5 g, 49.0 mmol) was dissolved in dichloromethane (130 mL), and imidazole (5 g, 73.4 mmol) and tert-butyldimethylsilyl chloride (7.75 g, 51.4 mmol) were added thereto. The reaction mixture was stirred at 0°C for 30 minutes and then at room temperature for 16 hours. After the reaction was completed, the reaction mixture was neutralized with a supersaturated sodium bicarbonate aqueous solution and extracted with ethyl acetate. The extracted organic layer was washed with distilled water, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The reaction mixture was purified by MPLC to obtain the target compound (4.7 g, 44%, clear oil).
[0647] Step 2: Preparation of ((1-(bromomethyl)cyclopropyl)methoxy)(tert-butyl)dimethylsilane
[0648]
[0649] The (1-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)methanol (1.1 g, 5.08 mmol) prepared in the above step 1 was dissolved in dichloromethane (10 ml), and carbon tetrabromide (1.85 g, 5.59 mmol) and triphenylphosphine (1.47 g, 5.59 mmol) were added thereto. The reaction mixture was stirred at 0° C. for 30 minutes and then at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure and purified by MPLC to obtain the target compound (1 g, 70%, clear oil).
[0650] Step 3: Preparation of (1-(bromomethyl)cyclopropyl)methanol
[0651]
[0652] The ((1-(bromomethyl)cyclopropyl)methoxy)(tert-butyl)dimethylsilane (1 g, 3.58 mmol) prepared in step 2 above was dissolved in acetic acid / tetrahydrofuran / distilled water (12 ml / 4 ml / 4 ml), and then stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was neutralized with a supersaturated sodium bicarbonate aqueous solution and extracted with ethyl acetate. The extracted organic layer was washed with distilled water, dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure. The resulting reaction mixture was purified by MPLC to obtain the target compound (0.3 g, 51%, yellow oil).
[0653] Step 4: 4-((1-(bromomethyl)cyclopropyl)methoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonate Preparation of amide
[0654]
[0655] According to the method similar to that described in step 2 of Example 92, using (1-(bromomethyl)cyclopropyl)methanol (30 mg, 0.182 mmol) prepared in step 3 above, N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-hydroxybenzenesulfonamide (66 mg, 0.182 mmol), triphenylphosphine (72 mg, 0.273 mmol) and diethyl azodicarboxylate (0.124 ml, 0.273 mmol) to obtain the title compound (45 mg, 48%, yellow solid).
[0656] Step 5: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((1-((4-methylpiperazin-1-yl)methyl)cyclopropane Preparation of 2-(4-(2-methoxy)benzenesulfonamide
[0657]
[0658] Following a procedure analogous to that described in Step 3 of Example 31, using 4-((1-(bromomethyl)cyclopropyl)methoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide (20 mg, 0.039 mmol) prepared in Step 4 above, 1-methylpiperazine (0.013 ml, 0.117 mmol) and potassium carbonate (8.1 mg, 0.059 mmol), the title compound (12.3 mg, 59%, yellow solid) was obtained.
[0659] The compound of Example 117 was prepared in a manner analogous to the method described in Example 116.
[0660] <Example 118> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)phenoxy)benzenesulfonamide
[0661]
[0662] Step 1: Preparation of 4-(3-bromophenoxy)benzenesulfonic acid
[0663]
[0664] 1-Bromo-3-phenoxybenzene (300 mg, 1.20 mmol) was dissolved in dichloromethane, and chlorosulfonic acid (0.088 ml, 1.33 mmol) was slowly added thereto at 0°C. The reaction mixture was stirred at 0°C for 30 minutes and then at room temperature for 3 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to obtain the target compound (395 mg, 100%, yellow oil).
[0665] Step 2: Preparation of 4-(3-bromophenoxy)benzenesulfonyl chloride
[0666]
[0667] At 0°C, 4-(3-bromophenoxy)benzenesulfonic acid (395 mg, 1.20 mmol) prepared in the above step 1 was dissolved in SnCl2·H2O (3 ml, 41.4 mmol), and then stirred. Then, two drops of diformamide were added thereto at 0°C, and the reaction mixture was gradually heated and stirred under reflux for 2 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, concentrated under reduced pressure, and purified by MPLC to obtain the target compound (380 mg, 91%, yellow oil).
[0668] Step 3: Preparation of 4-(3-bromophenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide
[0669]
[0670] By following a procedure similar to that described in Step 2 of Example 90, using 4-(3-bromophenoxy)benzenesulfonyl chloride (150 mg, 0.432 mmol), 3-(5-chloro-1H-indol-3-yl)propan-1-amine (90 mg, 0.432 mmol) and triethylamine (0.090 ml, 0.647 mmol) prepared in Step 2 above, the title compound (170 mg, 76%) was obtained as a yellow solid.
[0671] Step 4: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)phenoxy)benzenesulfonate Preparation of amides
[0672]
[0673] 4-(3-bromophenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide (90 mg, 0.173 mmol) prepared in step 3 above was dissolved in 1,4-dioxane (1.5 ml), and t-BuOK (29.1 mg, 0.260 mmol) and 1-methylpiperazine (0.03 ml, 0.260 mmol) were added thereto at room temperature. The reaction mixture was heated and stirred at 70°C, degassed with a nitrogen balloon for 5 minutes, and Pd(t-Bu3P)2 (8 mg, 0.016 mmol) was added thereto, followed by reflux stirring for 3 hours. After completion of the reaction, the reaction mixture was cooled to room temperature, filtered and concentrated with celite, and purified by preparative HPLC. The trifluoroacetic acid compound obtained was neutralized by adding a supersaturated sodium bicarbonate aqueous solution and extracted with a 10% methanol / dichloromethane solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to give the title compound (6.5 mg, 53%, white solid).
[0674] The compound of Example 119 was prepared in a manner analogous to the methods described in Steps 1 to 3 of Example 118.
[0675] The compounds of Examples 120 to 122 were prepared in a manner analogous to the method described in Example 118.
[0676] <Example 123> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-methylpiperazin-1-yl)phenyl)amino)benzenesulfonamide
[0677]
[0678]
[0679] The compound (0.05 g, 0.117 mmol) prepared in a manner similar to that described in Step 2 of Example 47 was dissolved in 2-butanol (1.5 ml), and 3-(4-methylpiperazin-1-yl)aniline (0.02 g, 0.117 mmol) and potassium carbonate (0.08 g, 0.584 mmol) were added thereto, followed by degassing for 1 minute. Then, Pd2(dba)3 (0.01 g, 0.012 mmol) and Xphos (0.005 g, 0.012 mmol) were added thereto at 80°C, followed by stirring at 100°C for 1 hour. After completion of the reaction, the reaction solution was filtered through celite and washed with ethyl acetate and dichloromethane. The filtrate was concentrated under reduced pressure, purified by preparative HPLC, and neutralized by adding aqueous sodium bicarbonate solution to give the target compound (0.023 g, 37%, yellow solid).
[0680] The compounds of Examples 124 to 127 were prepared in a manner analogous to the method described in Example 123.
[0681] The compounds of Examples 128 and 129 were prepared in a manner analogous to the method described in Example 119.
[0682] <Example 130> Preparation of 4-(3,5-bis(4-methylpiperazin-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide
[0683]
[0684] Step 1: Preparation of 1,3-dibromo-5-phenoxybenzene
[0685]
[0686] Phenol (100 mg, 1.06 mmol) was dissolved in N-methyl-2-pyrrolidone (2 ml), and cesium carbonate (173 mg, 0.531 mmol), 1,3-dibromo-5-fluorobenzene (0.201 ml, 1.59 mmol), TMDDA (0.057 ml, 0.266 mmol) and CuCl (52.6 mg, 0.531 mmol) were added thereto at room temperature. The reaction mixture was degassed with a nitrogen balloon at room temperature and then stirred for 20 minutes. The reaction mixture was gradually heated and stirred at 120 ° C for 16 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, filtered with diatomaceous earth, extracted with ethyl acetate, and concentrated under reduced pressure. The resulting reaction mixture was purified by MPLC to obtain the target compound (220 mg, 63%, yellow solid).
[0687] Step 2: Preparation of 4-(3,5-dibromophenoxy)benzenesulfonic acid
[0688]
[0689] In a manner similar to the method described in Step 1 of Example 118, the title compound (274 mg, 100%, yellow solid) was prepared using 1,3-dibromo-5-phenoxybenzene (220 mg, 0.671 mmol) prepared in Step 1 above and chlorosulfonic acid (0.049 ml, 0.738 mmol).
[0690] Step 3: Preparation of 4-(3,5-dibromophenoxy)benzenesulfonyl chloride
[0691]
[0692] In a manner similar to Example 118, Step 2, using 4-(3,5-dibromophenoxy)benzenesulfonic acid (274 mg, 0.671 mmol) prepared in Step 2 above and thionyl chloride (4 ml, 55.1 mmol), the title compound (230 mg, 80%, yellow solid) was obtained.
[0693] Step 4: Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3,5-dibromophenoxy)benzenesulfonamide
[0694]
[0695] Using a method similar to that in Step 2 of Example 90, using 4-(3,5-dibromophenoxy)benzenesulfonyl chloride (230 mg, 0.539 mmol), 3-(5-chloro-1H-indol-3-yl)propan-1-amine (118 mg, 0.566 mmol) and triethylamine (0.113 ml, 0.809 mmol) prepared in Step 3 above, the title compound (300 mg, 93%) was obtained as a white solid.
[0696] Step 5: 4-(3,5-bis(4-methylpiperazin-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl) Preparation of benzenesulfonamide
[0697]
[0698] Using a method similar to that in Step 4 of Example 118, using N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3,5-dibromophenoxy)benzenesulfonamide (50 mg, 0.084 mmol), 1-methylpiperazine (0.037 ml, 0.334 mmol), potassium tert-butoxide (37.5 mg, 0.334 mmol) and Pd(t-Bu3P)2 (8.54 mg, 0.017 mmol) prepared in Step 4 above, the title compound (5 mg, 9%, yellow solid) was obtained.
[0699] The compounds of Examples 131 to 134 were prepared in a manner analogous to the method described in Example 123.
[0700] The compounds of Examples 135 and 136 were prepared in a manner analogous to the method described in Example 118.
[0701] The compound of Example 137 was prepared in a manner analogous to the method described in Example 138.
[0702] <Example 138> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-bromo-5-(4-methylpiperazin-1-yl)phenoxy)benzenesulfonamide
[0703]
[0704] Step 1: Preparation of 1-bromo-3-fluoro-5-phenoxybenzene
[0705]
[0706] The title compound (0.45 g, 32%, clear oil) was prepared in a manner similar to the procedure described in Step 1 of Example 130 using phenol (0.5 g, 5.31 mmol), cesium carbonate (0.866 g, 2.66 mmol), 1-bromo-3,5-difluorobenzene (1.54 g, 7.97 mmol), TMHDA (0.284 ml, 1.33 mmol) and CuCl (0.263 mg, 2.66 mmol).
[0707] Step 2: Preparation of 4-(3-bromo-5-fluorophenoxy)benzene-1-sulfonyl chloride
[0708]
[0709] By a procedure similar to that described in Step 1, using 1-bromo-3-fluoro-5-phenoxybenzene (0.45 g, 1.685 mmol) prepared in Step 1 of Example 31 and chlorosulfonic acid (0.123 ml, 1.853 mmol), the title compound (0.44 g, 71%, yellow oil) was obtained.
[0710] Step 3: Preparation of 4-(3-bromo-5-fluorophenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide
[0711]
[0712] In a manner similar to the method described in Step 2 of Example 90, 4-(3-bromo-5-fluorophenoxy)benzene-1-sulfonyl chloride (200 mg, 0.547 mmol) prepared in Step 2 above, 3-(5-chloro-1H-indol-3-yl))propan-1-amine (115 mg, 0.553 mmol) and triethylamine (0.114 ml, 0.821 mmol) were used to obtain the title compound (300 mg, 93%) as a yellow solid.
[0713] Step 4: 4-(3-Bromo-5-(4-methylpiperazin-1-yl)phenoxy)-N-(3-(5-chloro-1H-indole-3-yl)- Preparation of 1-(2-propyl)benzenesulfonamide
[0714]
[0715] The 4-(3-bromo-5-fluorophenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide (30 mg, 0.056 mmol) prepared in the above step 3 was dissolved in dimethyl sulfoxide (1 ml), and 1-methylpiperazine (0.025 ml, 0.223 mmol) and potassium carbonate (30.8 mg, 0.223 mmol) were added thereto at room temperature. Then, the reaction mixture was heated at 120°C and stirred for 16 hours. After the reaction was completed, the mixture was cooled to room temperature, washed with distilled water and brine, and extracted with ethyl acetate. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by preparative HPLC. The trifluoroacetate compound obtained was neutralized by adding a supersaturated aqueous sodium bicarbonate solution, and then extracted with a 10% methanol / dichloromethane solution. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, and then concentrated under reduced pressure to obtain the target compound (6.2 mg, 22%, milky white solid).
[0716] The compounds of Examples 139-142 were prepared in a manner analogous to the method described in Example 123.
[0717] <Example 143> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzamide
[0718]
[0719] Step 1: Preparation of methyl 4-(3-bromopropoxy)benzoate
[0720]
[0721] Methyl 4-hydroxybenzoate (0.5 g, 3.29 mmol) was dissolved in acetonitrile (10 ml), and 1,3-dibromopropane (0.995 g, 4.93 mmol) and potassium carbonate (0.681 g, 4.93 mmol) were added thereto. The reaction mixture was heated at 80 ° C and stirred for 5 hours. After the reaction was completed, the mixture was cooled to room temperature, filtered through diatomaceous earth, and concentrated under reduced pressure. The obtained residue was purified by MPLC to obtain the target compound (0.7 g, 78%, clear oil).
[0722] Step 2: Preparation of 4-(3-bromopropoxy)benzoic acid
[0723]
[0724] The methyl 4-(3-bromopropoxy)benzoate (0.7 g, 2.56 mmol) prepared in step 1 above was dissolved in tetrahydrofuran / methanol / distilled water (6.0 ml / 3 ml / 3 ml), and LiOH·H2O (0.323 g, 7.69 mmol) was added thereto at room temperature. Then, the reaction mixture was heated at 50°C and stirred for 2 hours. After the reaction was completed, the mixture was cooled to room temperature, 1N hydrochloric acid aqueous solution was slowly added dropwise, the pH was adjusted to 2, and the obtained solid was washed with distilled water and then vacuum dried to obtain the target compound (0.35 g, 53%, white solid).
[0725] Step 3: Preparation of 4-(3-bromopropoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzamide
[0726]
[0727] 4-(3-bromopropoxy)benzoic acid (0.1 g, 0.386 mmol) prepared in step 2 above was dissolved in dichloromethane (2 ml), 3-(5-chloro-1H-indol-3-yl)propane-1-amine (0.081 g, 0.390 mmol), HATU (0.294 g, 0.772 mmol) and N,N-diisopropylethylamine (0.15 g, 1.158 mmol) were added thereto at room temperature, and then stirred at room temperature for 16 hours. After the reaction was completed, the mixture was washed with distilled water and extracted with dichloromethane. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and purified by MPLC to obtain the target compound (0.1 g, 58%, milky white solid).
[0728] Step 4: N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzyl Preparation of amides
[0729]
[0730] In a manner similar to the method described in Step 3 of Example 31, using 4-(3-bromopropoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzamide (20 mg, 0.044 mmol) prepared in Step 3 above, 1-methylpiperazine (0.02 ml, 0.178 mmol) and potassium carbonate (12.3 mg, 0.089 mmol), the title compound (8 mg, 38%, milky white solid) was obtained.
[0731] The compound of Example 144 was prepared in analogy to the method described in Example 143.
[0732] Example 145 was prepared in a manner similar to that described in Example 92.
[0733] <Example 146> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-2-((3-(piperazin-1-yl)propyl)amino)thiazole-5-sulfonamide
[0734]
[0735] Step 1: Preparation of 2-chloro-N-(3-(5-chloro-1H-indol-3-yl)propyl)thiazole-5-sulfonamide
[0736]
[0737] The title compound was prepared by a procedure similar to Example 31, Step 2.
[0738] Step 2: 4-(3-((5-(N-(3-(5-chloro-1H-indol-3-yl)propyl)sulfamoyl)thiazol-2-yl) Preparation of tert-butyl (amino)propyl)piperazine-1-carboxylate
[0739]
[0740] 2-Chloro-N-(3-(5-chloro-1H-indol-3-yl)propyl)thiazole-5-sulfonamide (30 mg, 0.077 mmol) prepared in step 1 above was dissolved in dimethylformamide, and tert-butyl 4-(3-aminopropyl)piperazine-1-carboxylate (28 mg, 0.115 mmol) and DIPEA (0.022 mL, 0.154 mmol) were added thereto. The reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed under reduced pressure, and then the reaction mixture was separated and purified by MPLC to obtain the target compound (37 mg, 81%, yellow solid).
[0741] Step 3: N-(3-(5-chloro-1H-indol-3-yl)propyl)-2-((3-(piperazin-1-yl)propyl)amino)thiazole- Preparation of 5-sulfonamide
[0742]
[0743] In a similar manner to that described in Step 3 of Example 99, the title compound (30 mg, 97%, light yellow solid) was obtained.
[0744] <Example 147> Preparation of N-(3-(5-chloro-2-methyl-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0745]
[0746] Step 1: Preparation of 3-(5-chloro-2-methyl-1H-indol-3-yl)propan-1-amine hydrochloride
[0747]
[0748] Chlorophenylhydrazine (1.40 g, 9.81 mmol) and 6-chlorohexen-2-one (1.10 g, 8.17 mmol) were dissolved in ethanol (30 ml) and then refluxed with stirring for 20 hours. After the reaction was completed, the mixture was cooled to room temperature and the solvent was removed under reduced pressure to obtain 3-(5-chloro-2-methyl-1H-indol-3-yl)propane-1-amine hydrochloride (2.114 g, quantitative, light yellow solid).
[0749] Step 2: Preparation of 4-(3-bromopropoxy)-N-(3-(5-chloro-2-methyl-1H-indol-3-yl)propyl)benzenesulfonamide Preparation
[0750]
[0751] 3-(5-chloro-2-methyl-1H-indol-3-yl)propane-1-amine hydrochloride (0.413g, 1.59mmol) prepared in the above step 1 was dissolved in ethylene chloride (6ml), triethylamine (0.444ml, 3.19mmol) was added dropwise thereto, and then stirred for 5 minutes. 4-(3-bromopropoxy)benzene-1-sulfonyl chloride (0.200g, 0.638mmol) was added dropwise thereto, and then stirred at room temperature for 1 hour. Water was added dropwise thereto to terminate the reaction, and then extracted with dichloromethane. The extracted organic layer was dried over anhydrous sodium sulfate and filtered, and the solvent was removed under reduced pressure. Then, the mixture was separated and purified by MPLC to obtain the target compound (177mg, 56%, brown solid).
[0752] Step 3: N-(3-(5-chloro-2-methyl-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy Preparation of 2-(4-(2-aminophenyl)benzenesulfonamide
[0753]
[0754] In a similar manner to the procedure described in step 3 of Example 31, the target compound (19.8 mg, 64%, pale yellow solid) was obtained.
[0755] <Example 148> Preparation of N-(3-(5-chloro-2-methyl-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0756]
[0757] 4-(4-bromobutyl)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide (30 mg, 0.062 mmol) prepared in step 2 of Example 90 was dissolved in acetonitrile, potassium carbonate (25.7 mg, 0.186 mmol) and 1H-imidazole (8.44 mg, 0.124 mmol) were added at room temperature, and stirred at 60°C for 4 hours. After the reaction was completed, the mixture was filtered through celite. The filtrate was concentrated under reduced pressure, and then separated and purified by MPLC to obtain the target compound (13 mg, 45%, white solid).
[0758] <Example 149> Preparation of N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0759]
[0760] Step 1: Preparation of 2-((5-chloro-1H-indol-3-yl)methyl)aniline
[0761]
[0762] 5-Chloro-1H-indole (1 g, 6.60 mmol) and (2-aminophenyl)methanol (0.812 g, 6.60 mmol) were dissolved in 1,2-dichloroethane (20 mL), trifluoroacetic acid (0.151 mL, 1.979 mmol) was added thereto at room temperature, and then stirred at 50° C. for 16 hours. After the mixture was cooled to room temperature, a supersaturated sodium carbonate aqueous solution was added dropwise to terminate the reaction, and then extracted with ethyl acetate. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, and then separated and purified by MPLC to obtain the target compound (0.55 g, 33%, yellow solid).
[0763] Step 2: Preparation of 4-(3-bromopropoxy)-N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)benzenesulfonamide Preparation
[0764]
[0765] The title compound was prepared by a procedure similar to Example 31, Step 2.
[0766] Step 3: N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy Preparation of 2-(4-(2-aminophenyl)benzenesulfonamide
[0767]
[0768] In a similar manner to that described in Example 148, the target compound (13.2 mg, 64%, pale yellow solid) was obtained.
[0769] The compound of Example 150 was prepared in a manner analogous to the method described in Example 149.
[0770] <Example 151> Preparation of N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0771]
[0772] Step 1: Preparation of 4-((5-chloro-1H-indol-3-yl)butan-2-one
[0773]
[0774] 5-Chloro-1H-indole (1 g, 6.60 mmol) was dissolved in distilled water (20 mL), and 3-butene-2-one (1.387 g, 19.79 mmol) and trifluoromethanesulfonic acid (10 mg, 0.066 mmol) were added thereto at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the mixture was washed with a supersaturated sodium carbonate aqueous solution and then extracted with ethyl acetate. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, and then separated and purified by MPLC to obtain the target compound (0.64 g, 44%, light yellow solid).
[0775] Step 2: Preparation of 4-(5-chloro-1H-indol-3-yl)butan-2-amine
[0776]
[0777] 4-((5-chloro-1H-indol-3-yl)butan-2-one (200 mg, 0.902 mmol) prepared in the above step 1 was dissolved in methanol (8 mL), and ammonium acetate (695 mg, 9.02 mmol) and sodium cyanoborohydride (283 mg, 4.51 mmol) were added thereto at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the mixture was washed with a supersaturated aqueous sodium carbonate solution and then extracted with ethyl acetate, and the extracted organic layer was dried over anhydrous sodium sulfate, filtered, separated and purified by MPLC to obtain the target compound (0.2 g, 100%, light yellow oil).
[0778] Step 3: Preparation of 4-(3-bromopropoxy)-N-(4-(5-chloro-1H-indol-3-yl)butan-2-yl)benzenesulfonamide
[0779]
[0780] The title compound was prepared by a procedure similar to Example 31, Step 2.
[0781] Step 4: N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(4-methylpiperazin-1-yl) Preparation of (propyloxy)benzenesulfonamide
[0782]
[0783] In a similar manner to Example 149, the title compound (16 mg, 77%, white solid) was prepared.
[0784] The compound of Example 152 was prepared in a similar manner to Example 151.
[0785] <Example 153> Preparation of N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide
[0786]
[0787] Step 1: Preparation of 3-(5-bromo-1H-indol-3-yl)propan-1-ol
[0788]
[0789] (4-Bromophenyl)hydrazine hydrochloride (1 g, 4.47 mmol) was dissolved in acetonitrile (10 ml), and a 4% aqueous sulfuric acid solution (10 ml) was added thereto. 3,4-dihydro-2H-pyran (0.40 ml, 4.47 mmol) was slowly added thereto at 100° C. for 2 minutes, and then stirred at 100° C. for 2 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (0.61 g, 54%).
[0790] Step 2: Preparation of 5-bromo-3-(3-bromopropyl)-1H-indole
[0791]
[0792] The compound prepared in step 1 above (0.31 g, 1.231 mmol) was dissolved in dichloromethane (2 ml), and carbon tetrabromide (0.49 g, 1.477 mmol) and triphenylphosphine (0.38 g, 1.477 mmol) were added thereto at 0°C. The reaction mixture was stirred for 30 minutes and then stirred at room temperature for 4 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure and then purified by MPLC to obtain the target compound (0.29 g, 77%).
[0793] Step 3: Preparation of 3-(3-azidopropyl)-5-bromo-1H-indole
[0794]
[0795] The compound prepared in step 2 above (0.99 g, 3.25 mmol) was dissolved in dimethylformamide (11 ml), sodium azide (1.05 g, 16.24 mmol) was added thereto, and then stirred at room temperature for 4 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (0.54 g, 62%).
[0796] Step 4: Preparation of 3-(5-bromo-1H-indol-3-yl)propan-1-amine
[0797]
[0798] The compound prepared in step 3 above (0.1 g, 0.358 mmol) was dissolved in tetrahydrofuran (3 ml) and water (0.2 ml), triphenylphosphine (0.47 g, 1.791 mmol) was added thereto, and then stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (0.075 g, 83%).
[0799] Step 5: Preparation of N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-bromopropoxy)benzenesulfonamide
[0800]
[0801] The compound (0.094 g, 0.299 mmol) obtained in step 1 of Example 31 was dissolved in dichloromethane (1 ml), and the compound (0.075 g, 0.299 mmol) obtained in step 4 above and potassium carbonate (0.124 g, 0.896 mmol) were added thereto, followed by stirring at room temperature for 1 hour. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (0.12 g, 80%).
[0802] Step 6: Preparation of N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide preparation
[0803]
[0804] The compound prepared in step 5 above (0.06 g, 0.113 mmol) was dissolved in ethanol (1.5 ml), potassium carbonate (0.031 g, 0.226 mmol) and piperazine (0.02 g, 0.339 mmol) were added thereto, and then stirred at 70° C. for 16 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, diluted with dichloromethane, and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, purified by preparative HPLC, and the target compound (0.032 g, 53%, yellow solid) was obtained by adding sodium bicarbonate aqueous solution.
[0805] The compounds of Examples 154 to 156 were prepared in a manner analogous to the method described in Example 153.
[0806] The compound of Example 147 was prepared in a manner analogous to the method described in Example 147.
[0807] The compounds of Examples 158 and 159 were prepared in a manner analogous to the method described in Example 31.
[0808] The compounds of Examples 160 and 161 were prepared in a manner analogous to the method described in Example 148.
[0809] The compounds of Examples 162 and 163 were prepared in a manner analogous to the method described in Example 31.
[0810] The compounds of Examples 164 and 165 were prepared in a manner analogous to the method described in Example 153.
[0811] The compound of Example 148 was prepared in a manner analogous to the method described in Example 148.
[0812] <Example 167> Preparation of N-(3-(5-chloro-1H-indazol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0813]
[0814] Step 1: Preparation of (cyanomethyl)triphenylphosphonium
[0815]
[0816] 2-Bromoacetonitrile (1.328 mL, 19.06 mmol) was dissolved in dichloromethane (80 mL), triphenylphosphine (5 g, 19.06 mmol) was added thereto at room temperature, and then stirred for 6 hours. After the reaction was completed, the mixture was washed with ether without further purification to obtain the target compound (7 g, 96%, white solid).
[0817] Step 2: Preparation of (E)-3-(5-chloro-1H-indazol-3-yl)acrylonitrile
[0818]
[0819] The (cyanomethyl) triphenylphosphonium (3.17 g, 8.31 mmol) prepared in step 1 above was dissolved in anhydrous tetrahydrofuran (10 mL), sodium tert-butoxide (0.8 g, 8.31 mmol) was added thereto at -78 ° C, and then stirred for 30 minutes. At -78 ° C, 5-chloro-1H-indazole-3-carboxaldehyde (1.0 g, 5.44 mmol) was dissolved in anhydrous tetrahydrofuran and added thereto. The temperature of the reaction mixture was slowly raised to room temperature and then stirred for 1 hour. After the reaction was completed, the mixture was washed with a supersaturated aqueous ammonium chloride solution and extracted with ethyl acetate. The extracted organic layer was dried over anhydrous sodium sulfate, filtered, and then separated and purified by MPLC to obtain the target compound (0.3 g, 27%, light yellow solid).
[0820] Step 3: Preparation of 3-(5-chloro-1H-indazol-3-yl)propan-1-amine
[0821]
[0822] The (E)-3-(5-chloro-1H-indazole-3-yl)acrylonitrile (300 mg, 1.473 mmol) prepared in step 2 above was dissolved in ether (5 mL), and LAH (168 mg, 4.42 mmol) was added thereto at -78 ° C. The temperature of the reaction mixture was slowly raised to room temperature, followed by stirring for 2 hours. The reaction was terminated by the additional addition of LAH (112 mg, 2.95 mmol). After the reaction was completed, the mixture was filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, then separated and purified by MPLC to obtain the target compound (200 mg, 65%, yellow oil).
[0823] Step 4: Preparation of 4-(-bromopropoxy)-N-(3-(5-chloro-1H-indazol-3-yl)propyl)benzenesulfonamide
[0824]
[0825] In a similar manner to Example 31, Step 2, the title compound (75 mg, 18%, white solid) was prepared.
[0826] Step 5: N-(3-(5-chloro-1H-indazol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonate Preparation of amides
[0827]
[0828] The title compound (13.3 mg, 85%, pale yellow solid) was prepared in a similar manner to Example 148.
[0829] The compounds of Examples 168 to 170 were prepared in a similar manner to that in Example 167.
[0830] <Example 171> Preparation of (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0831]
[0832] Step 1: (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(oxiran-2-ylmethoxy)benzenesulfonyl Preparation of amines
[0833]
[0834] The compound prepared in step 1 of Example 92 (0.41 g, 1.026 mmol) was dissolved in dimethylformamide (3.4 ml), and (R)-2-(chloromethyl)oxirane (0.095 g, 1.026 mmol) and potassium carbonate (0.21 g, 1.539 mmol) were added thereto, and stirred at 60° C. for 16 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by MPLC to obtain the target compound (0.16 g, 37%).
[0835] Step 2: (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(2-hydroxy-3-(4-methylpiperazin-1-yl) Preparation of (propyloxy)benzenesulfonamide
[0836]
[0837] The compound prepared in step 1 above (0.083 g, 0.198 mmol) was dissolved in acetone (1 ml), 1-methylpiperazine (0.19 g, 1.981 mmol) and potassium carbonate (0.274 g, 1.981 mmol) were added thereto, and then stirred at 80°C for 16 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane and washed with water and brine. The residue of the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated, purified by preparative HPLC, and added to aqueous sodium bicarbonate solution to obtain the target compound (0.030 g, 30%, yellow solid).
[0838] The compounds of Examples 172 to 174 were prepared in a manner analogous to the method described in Example 171.
[0839] The compounds of Examples 175 and 176 were prepared in a manner analogous to the method described in Example 148.
[0840] <Example 177> Preparation of N-((6-chloro-2,3,4,9-tetrahydro-1H-carbazole-3-yl)methyl)4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0841]
[0842] Step 1: Preparation of 4-(3-bromopropoxy)-N-(3-(5-chloro-1H-indazol-3-yl)propyl)benzenesulfonamide
[0843]
[0844] Using (6-chloro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methanamine prepared in a manner similar to that described in reference [WO2006 / 89053], the target compound was obtained by a procedure similar to that described in Step 2 of Example 31.
[0845] Step 2: N-((6-chloro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)4-(3-(4-methylpiperazin-1-yl) Preparation of (propyloxy)benzenesulfonamide
[0846]
[0847] The target compound (6.3 mg, 20%, pale yellow solid) was obtained in a manner similar to that described in Example 148.
[0848] The compound of Example 178 was prepared in a manner similar to that described in Example 177.
[0849] The compounds of Examples 179 and 180 were prepared in a manner similar to that described in Example 85.
[0850] <Example 181> Preparation of N-(2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)phenyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide
[0851]
[0852] Step 1: Preparation of N-(2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)phenyl)-4-methylbenzenesulfonamide
[0853]
[0854] 5-Chloro-1H-indole (0.400 g, 5.28 mmol) and N-(2-(2-hydroxypropane-2-yl)phenyl)-4-methylbenzenesulfonamide (0.967 g, 3.17 mmol) were dissolved in 1,2-dichloroethane (40 ml), PdCl2·(CH3CN)2 (0.0340 g, 0.132 mmol) was added thereto, and then stirred for 3 hours in a nitrogen atmosphere. After the reaction was completed, the reaction mixture was cooled to room temperature, the solvent was removed under reduced pressure, separated and purified by MPLC to obtain the target compound (1.02 g, 88%, white solid).
[0855] Step 2: Preparation of 2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)aniline
[0856]
[0857] N-(2-(2-(5-chloro-1H-indol-3-yl)propane-2-yl)phenyl)-4-methylbenzenesulfonamide (0.540 g, 1.23 mmol) prepared in step 1 above was dissolved in sulfuric acid (6 mL), and then stirred at room temperature for 40 minutes. After adding ice to the reaction product to terminate the reaction, 2N sodium hydroxide aqueous solution was added dropwise to neutralize. The reaction mixture was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, then separated and purified by MPLC to obtain the target compound (0.175 g, 50%, light yellow solid).
[0858] Step 3: 4-(3-bromopropoxy)-N-(2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)phenyl)benzenesulfonyl Preparation of amines
[0859]
[0860] The target compound was obtained in a similar manner to that described in Step 2 of Example 31.
[0861] Step 4: N-(2-(2-(5-chloro-1H-indol-3-yl)propan-2-yl)phenyl)-4-(3-(4-methylpiperazine-1-yl)phenyl)- Preparation of (1-(2-propyl)propoxy)benzenesulfonamide
[0862]
[0863] The target compound (17.2 mg, 33%, pale yellow solid) was obtained in a manner similar to that described in Example 148.
[0864] The compound of Example 182 was prepared in analogy to the method described in Example 181.
[0865] The compounds of Examples 183 and 184 were prepared in a manner similar to that described in Example 153.
[0866] <Example 185> Preparation of N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(pyridin-4-yloxy)propyl)benzenesulfonamide
[0867]
[0868] In a manner analogous to that described in Example 148, using 4-(3-bromopropyl)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide prepared in a manner analogous to that described in steps 1 and 2 of Example 90, the title compound (18.5 mg, 60%, white solid) was obtained.
[0869] The compound of Example 186 was prepared in a manner analogous to that described in Example 185.
[0870] The compounds of Examples 187 to 190 were prepared in a manner analogous to the method described in Example 177.
[0871] Table 1 below summarizes the compound names, structural formulas and 1 H NMR and MS analysis results.
[0872]
Table 1
[0873]
[0874]
[0875]
[0876]
[0877]
[0878]
[0879]
[0880]
[0881]
[0882]
[0883]
[0884]
[0885]
[0886]
[0887]
[0888]
[0889]
[0890]
[0891]
[0892]
[0893]
[0894]
[0895]
[0896]
[0897]
[0898]
[0899]
[0900]
[0901]
[0902]
[0903]
[0904]
[0905]
[0906]
[0907]
[0908]
[0909]
[0910]
[0911]
[0912]
[0913]
[0914]
[0915]
[0916]
[0917]
[0918]
[0919]
[0920]
[0921]
[0922]
[0923]
[0924]
[0925]
[0926]
[0927]
[0928]
[0929]
[0930]
[0931]
[0932]
[0933]
[0934]
[0935]
[0936]
[0937]
[0938]
[0939]
[0940]
[0941]
[0942]
[0943]
[0944]
[0945]
[0946]
[0947]
[0948]
[0949]
[0950]
[0951]
[0952]
[0953]
[0954]
[0955]
[0956]
[0957]
[0958]
[0959]
[0960]
[0961]
[0962]
[0963]
[0964]
[0965]
[0966]
[0967]
[0968]
[0969]
[0970]
[0971]
[0972]
[0973]
[0974]
[0975]
[0976]
[0977]
[0978]
[0979]
[0980]
[0981]
[0982]
[0983]
[0984]
[0985]
[0986]
[0987]
[0988]
[0989]
[0990]
[0991]
[0992]
[0993]
[0994]
[0995]
[0996]
[0997]
[0998]
[0999]
[1000]
[1001]
[1002]
[1003]
[1004]
[1005]
[1006]
[1007]
[1008]
[1009]
[1010]
[1011]
[1012]
[1013]
[1014]
[1015]
[1016]
[1017]
[1018]
[1019]
[1020]
[1021]
[1022]
[1023]
[1024]
[1025]
[1026]
[1027]
[1028]
[1029]
[1030]
[1031]
[1032]
[1033]
[1034]
[1035]
[1036]
[1037]
[1038]
[1039]
[1040]
[1041]
[1042]
[1043]
[1044]
[1045]
[1046]
[1047]
[1048]
[1049]
[1050]
[1051]
[1052]
[1053]
[1054]
[1055]
[1056]
[1057]
[1058]
[1059]
[1060]
[1061]
[1062]
[1063]
[1064]
[1065]
[1066]
[1067]
[1068]
[1069]
[1070]
[1071]
[1072]
[1073]
[1074]
[1075]
[1076]
[1077]
[1078]
[1079]
[1080]
[1081]
[1082]
[1083] <Analysis and purification conditions>
[1084] [LC-MS analysis conditions]
[1085] Equipment name: Shimadzu LCMS-2020
[1086] Column: ACE Excel2 C18, 75×2.1mm
[1087] Mobile phase: acetonitrile / H2O+0.1% TFA
[1088] Flow rate: 0.5mL / min
[1089] UV detector: 254nm
[1090] [MPLC purification conditions]
[1091] Device Name: Rf+
[1092] UV detector: 254nm
[1093] [Preparative HPLC purification conditions]
[1094] Equipment name: Gilson GX-281, 321 pump, UV / VIS-155
[1095] column: 10νM C18(2) 250x21.2 mm
[1096] Mobile phase: acetonitrile / 0.1% TFA H2O
[1097] Flow rate: 18mL / min
[1098] UV detector: 254nm
[1099] [ 1 H NMR]
[1100] Equipment name: Bruker Avance (400MHz)
[1101] <Experimental Example 1> Evaluation of Pin1 enzyme inhibitory activity
[1102] In order to evaluate the inhibitory activity of the compound represented by Formula 1 of the present invention on the Pin1 enzyme, the following experiment was conducted and the results are shown in Table 2 below.
[1103] The enzymatic activity of Pin1 protein was measured using the Sensolyte Green Pin1 Assay Kit from Anaspec. The substrate was diluted 1:100 in buffer to prepare a concentration of 1 μM, and the protein was diluted 1:20 in buffer to prepare a concentration of 50 μg / ml. In addition, the developer was prepared by diluting 1:100 in buffer.
[1104] The compound prepared in each example was diluted with DMSO and prepared with a buffer solution to a concentration of 100 μM, 10 μM, 1 μM or 0.1 μM. 10 μl of the compound prepared in each example diluted to four concentrations according to the above method, 10 μl of Pin 1 protein and 30 μl of developer were added to each well of a black 96-well plate in sequence, and finally 50 μl of substrate was added. Finally, 50 μl of substrate was added to each well of the plate, and the enzyme reaction was performed after shaking the plate for 10 seconds.
[1105] Then, the plate was incubated at room temperature for 2 hours in a lightless environment, and the fluorescence value at 490 nm / 520 nm wavelength was measured using a device from Synergy Neo (Tecan). The results are shown in Table 2 below by ranking A to D for each concentration (μM) at which Pin1 enzyme activity was inhibited.
[1106] [Table 2]
[1107]
[1108]
[1109]
[1110] *A<1μM, 1μM <B<10μM、10μM<C<100μM、100μM<D
[1111] As shown in Table 2, it can be confirmed that when using Examples 56, 61, 66, 70, 75, 77, 79, 83, 86, 87, 88, 90, 91, 92, 93, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 112, 113, 114, 115, 116, 117, 118, 121, 123, 124, 125, 127, 130, 133, 134, 137, 138, 140, 141 1, 143, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 158, 159, 160, 161, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 183, 184, 185, 186, 187, 188, 189 or 190 shows Pin1 inhibitory activity at a concentration of less than 1 μM.
[1112] The above results show that the compounds of the examples of the present invention are excellent in inhibiting Pin1 enzyme. Therefore, it can be seen that the benzenesulfonamide derivative compounds according to the present invention can be effectively used as a pharmaceutical composition for preventing or treating cancer.
[1113] <Experimental Example 2> Evaluation of protein expression inhibition ability of MDA-MB 231 triple-negative breast cancer cell line
[1114] In order to confirm the ability of the compound represented by Formula 1 of the present invention to inhibit protein expression of MDA-MB 231 triple-negative breast cancer cell line, the following experiment was conducted, and the results are shown in Table 3 below.
[1115] MDA-MB-231 cells were cultured in a 37°C, 5% CO2 incubator using RPMI medium supplemented with 10% FBS and 1% penicillin / streptomycin.
[1116] The cells were washed once a day with PBS and then replaced with fresh medium. One day before the detachment experiment with trypsin / EDTA, the cells were grown to at least 90% density and then plated at a density of 100,000 / well in 6-well plates.
[1117] On the second day of culture, the compound prepared in each example was treated at a concentration of 10 μM, and DMSO was treated at a concentration of 0.1% of the total amount as a control, followed by incubation for 72 hours. After 72 hours, the cells were washed twice with PBS, collected by scraping, and centrifuged at 13,000 rpm for 3 minutes to remove all the supernatant and only the cells.
[1118] RIPA buffer (containing 1X protease inhibitors and phosphatase inhibitors) was added to the prepared cells (80 μl / well), and the plate was shaken once every 5 minutes to break the cells for a total of 15 minutes. The broken cells were centrifuged at 13,000 rpm for 15 minutes to collect only the supernatant protein. The protein obtained was quantified using a BCA protein quantification kit (Pierce, MA, USA), and a total of 10 μg of protein was used for Western blotting.
[1119] Protein samples were separated by 10% SDS-PAGE and transferred to PVDF membranes. Anti-human cyclin D1 antibody (cell signaling) and anti-vinculin antibody were bound to the protein samples, and the expression of the protein was measured by using ECL reagent and LAS4000 equipment. The measurement results were quantified and summarized using ImageJ. The results were divided into grades A to D according to the amount of protein compared to the DMSO-treated control group, and the results are shown in Table 3 below.
[1120] [Table 3]
[1121]
[1122] *0 <A<35%,35%<B<50%,50%<C<70%,70%<D<100%。
[1123] As shown in Table 3, when treated with the compound of Examples 35, 61, 66, 70, 75, 77, 78, 79, 81, 83, 91, 92, 93, 98, 99 or 121, the expression level of the protein in the MDA-MB 231 triple negative breast cancer cell line was found to be less than 35% compared to the DMSO treated control group.
[1124] The above results show that the compounds of the examples of the present invention have excellent ability to inhibit protein expression in MDA-MB 231 triple-negative breast cancer cell line. Therefore, it can be seen that the benzenesulfonamide derivative compounds of the present invention can be effectively used as a pharmaceutical composition for preventing or treating cancer.
[1125] <Experimental Example 3> Evaluation of cell viability of MCF7, MCF7-SP, A2780 or A2780-SP cells
[1126] In order to confirm the inhibitory effect of the compound of formula 1 of the present invention on the growth of MCF7, MCF7-SP, A2780 or A2780-SP cells, the following experiment was conducted and the results are shown in Tables 4 and 5 below.
[1127] MCF7 cells (breast cancer cells) were seeded in 96-well plates at a density of 3000 viable cells / well and cultured in DMEM / high glucose medium supplemented with 10% FBS and 1% penicillin / streptomycin.
[1128] On the second day of culture, cells were treated with the compound of Example 71, 76, 80, 84, 92, 99, 100 or 119 and then cultured for 3 days. Cell viability was evaluated by cell titer GLO (Promega, WC, USA), and luciferase activity was detected using a Tecan plate reader (Biocompare, USA).
[1129] On the other hand, MCF7-SP cells (breast cancer stem cells) were plated at a density of 1,500 viable cells / well in ultra-low attachment round-bottom 96-well plates (corning) and cultured in cancer stem cell medium. The cancer stem cell medium consists of neural cell basal medium supplemented with 20 ng / ml bFGF, 10 ng / ml EGF, 2.5 ng / ml amphotericin B, HEPES, Glutamax, and B27.
[1130] On the second day of culture, the cells were treated with the compound of Example 71, 76, 80, 84, 92, 99, 100 or 119 and then cultured for 8 days. The medium containing the compound was added again on day 4. The sphere cell viability was evaluated by Cell-Titer Glo (Promega, WC, USA), and the luciferase activity was detected using a Tecan plate reader (Biocompare, USA).
[1131] In addition, A2780 cells (ovarian cancer cells) were seeded in a 96-well plate at a density of 3000 viable cells / well and cultured in RPMI-1640 medium supplemented with 10% FBS and 1% penicillin / streptomycin.
[1132] On the second day of culture, cells were treated with the compounds of Examples 57 and 69 to 144 and then cultured for 3 days. Cell viability was evaluated by Cell-titer Glo (Promega, WC, USA), and luciferase activity was detected using a Tecan plate reader (Biocompare, USA).
[1133] On the other hand, A2780-SP cells (ovarian cancer stem cells) were seeded at a density of 1,500 live cells / well in an ultra-low attachment round-bottom 96-well plate (Corning) and cultured in cancer stem cell medium. The cancer stem cell medium consisted of neurobasal medium supplemented with 20 ng / ml bFGF, 10 ng / ml EGF, 2.5 ng / ml amphotericin B, HEPES, Glutamax, and B27.
[1134] On the second day of culture, cells were treated with the compounds of Examples 57 and 69 to 144 and then cultured for 8 days. The medium containing the compound was added thereto again on the 4th day. The viability of sphere cells was evaluated by Cell-Titer Glo (Promega, WC, USA), and luciferase activity was detected using a Tecan plate reader (Biocompare, USA).
[1135] [Table 4]
[1136] Example MCF7 MCF7-SP 70 B B 75 B C 79 C C 83 B B 91 B B 98 C C 99 B B 118 B B
[1137] *A < 1 μM, 1 μM < B < 10 μM, 10 μM < C. [Table 5]
[1138]
[1139]
[1140] *A < 1 μM, 1 μM < B < 10 μM, 10 μM < C, -: not detected.
[1141] As shown in Table 4, when treated with the compounds of Examples 70, 75, 83, 91, 99, or 118, the concentration of MCF7 cells was less than 10 μM, and when treated with the compounds of Examples 70, 83, 91, 99, or 118, the concentration of MCF7-SP cells was less than 10 μM.
[1142] As shown in Table 5, when treated with the compound of Examples 56, 59, 61, 66, 70, 75, 83, 93, 98, 99, 100, 106, 108, 109, 121, 123, 124, 130, 153, 154, 164, 165, 167, 169, 170, 173, 175, 176, 177 or 178, the A2780 cell concentration was less than 10 μM, and when treated with the compound of Examples 56, 59, 61, 66, 70, 79, 83, 88, 90, 91, 92, 93, 99 , 100, 103, 104, 105, 106, 108, 109, 110, 111, 112, 115, 118, 121, 134, 150, 151, 152, 153, 154, 157, 158, 159, 161, 164, 165, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 183, 184, 189, 187, 188 or 190 is treated with the compound at a concentration of less than 1 μM.
[1143] The above results show that the example compounds of the present invention have excellent inhibitory effects on the growth of MCF7, MCF7-SP, A2780 or A2780-SP cells. Therefore, it can be seen that the benzenesulfonamide derivative compounds of the present invention can be effectively used as a pharmaceutical composition for preventing or treating cancer.
Claims
1. A compound represented by Formula 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof: [Formula 1] in, Ar is a 6-10 membered aryl group or a 5-6 membered heteroaryl group containing one or more heteroatoms selected from N, S and O; R 1 and R 2 are independently hydrogen or halogen; R 3 is a substituted straight or branched chain C 1-8 Alkyl, NR a1 R a2 OR a3 , Where R a1 It is hydrogen, R a2 and R a3 are independently substituted straight or branched chain C 1-8 alkyl, substituted phenyl or substituted 5-6 membered heteroaryl containing one or more N heteroatoms, wherein the substituted alkyl is substituted with a substituent of an unsubstituted or substituted 4-8 membered heterocycloalkyl containing one or more heteroatoms selected from N, S and O, and the substituted alkyl is optionally further substituted to form a 3-6 membered cycloalkyl with each independently substituted carbon, The substituted phenyl and the substituted 5-6 membered heteroaryl are independently substituted with one or more substituents selected from 4-8 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, and The substituted 4-8 membered heterocycloalkyl is substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more halogen straight or branched chain C 1-5 Alkyl, linear or branched C 1-5 Alkylcarbonyl, NR b1 R b2 , halogen, hydroxy and oxo, R b1 and R b2 are independently hydrogen, or a linear or branched C 1-6 alkyl; L 1 for Where R c is hydrogen; L 2 is a straight or branched chain C 1-8 Alkylene; Z is a C fused to an unsubstituted or substituted 9-membered heteroaryl group containing one or more N heteroatoms. 3-8 Cycloalkyl, or a substituted 9-membered heteroaryl containing one or more N heteroatoms, Wherein, the substituted 9-membered heteroaryl is substituted by one or more halogens.
2. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Ar is a 6-10 membered aryl group or a 5-6 membered heteroaryl group containing one or more heteroatoms selected from N, S and O; R 1 and R 2 are independently hydrogen or fluorine; R 3 is a substituted straight or branched chain C 1-6 Alkyl, NR a1 R a2 OR a3 Where R a1 It is hydrogen, R a2 and R a3 are independently substituted straight or branched chain C 1-6 alkyl, substituted phenyl or substituted 5-6 membered heteroaryl containing one or more N heteroatoms, wherein the substituted alkyl is substituted with a substituent of an unsubstituted or substituted 4-7 membered heterocycloalkyl containing one or more heteroatoms selected from N, S and O, and the substituted alkyl is optionally further substituted to form a 3-5 membered cycloalkyl with each independently substituted carbon, The substituted phenyl and the substituted 5-6 membered heteroaryl are independently substituted with one or more substituents selected from 4-7 membered unsubstituted or substituted heterocycloalkyl containing one or more heteroatoms selected from N, S and O, and The substituted 4-7 membered heterocycloalkyl is substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more halogen straight or branched chain C 1-4 Alkyl, linear or branched C 1-4 Alkylcarbonyl, NR b1 R b2 , chlorine, fluorine, bromine, hydroxy and oxo, R b1 and R b2 are independently hydrogen, or a linear or branched C 1-3 alkyl; L 1 for Where R c is hydrogen; L 2 is an unsubstituted or hydroxy-substituted straight or branched chain C 1-6 Alkylene; Z is a C fused to an unsubstituted or substituted 9-membered heteroaryl group containing one or more N heteroatoms. 4-7 Cycloalkyl, or a substituted 9-membered heteroaryl containing one or more N heteroatoms, Wherein, the substituted 9-membered heteroaryl is substituted by one or more substituents selected from fluorine, chlorine and bromine.
3. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Ar is phenyl, naphthyl, pyridyl or thiazolyl; R 1 and R 2 are independently hydrogen or fluorine; R 3 is a substituted straight or branched chain C 1-5 Alkyl, NR a1 R a2 OR a3 Where R a1 It is hydrogen, R a2 and R a3 are independently substituted straight or branched chain C 1-5 alkyl, substituted phenyl or substituted 5-6 membered heteroaryl containing one or more N heteroatoms, wherein the substituted alkyl is substituted with a substituent selected from an unsubstituted or substituted 4-7 membered heterocycloalkyl containing one or more N heteroatoms, and the substituted alkyl is optionally further substituted to form a cyclopropyl group with each independently substituted carbon, The substituted phenyl and the substituted 5-6 membered heteroaryl are independently substituted with one or more substituents selected from unsubstituted or substituted 4-7 membered heterocycloalkyl containing one or more heteroatoms selected from N, S and O, and The substituted 4-7 membered heterocycloalkyl is substituted by one or more substituents selected from the following: unsubstituted or substituted by one or more fluorine straight or branched chain C 1-3 Alkyl, linear or branched C 1-4 Alkylcarbonyl, NR b1 R b2 , chlorine, fluorine, bromine, hydroxy and oxo, R b1 and R b2 are independently hydrogen, methyl or ethyl; L 1 for Where R c is hydrogen; L 2 is an unsubstituted or hydroxy-substituted straight or branched chain C 1-4 Alkylene; Z is a C fused to an unsubstituted or substituted 9-membered heteroaryl group containing one or more N heteroatoms. 5-6 cycloalkyl, or a substituted 9-membered heteroaryl containing one or more N heteroatoms, Wherein, the substituted 9-membered heteroaryl is substituted by one or more substituents selected from fluorine, chlorine and bromine.
4. The compound according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: Ar is phenyl, naphthyl, pyridyl or thiazolyl; R 1 and R 2 are independently hydrogen or fluorine; R 3 for L 1 yes L 2 for Z is 5. The following compounds, their stereoisomers or pharmaceutically acceptable salts: <56> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <59> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonamide; <61> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <63> 4-(3-(4-ethylpiperazin-1-yl)propoxy)-N-(3-(5-fluoro-1H-indol-3-yl)propyl)benzenesulfonamide; <66> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <70> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <72> 4-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propoxy)-N-(3-(5-fluoro-1H-indol-3-yl)propyl)benzenesulfonamide; <73> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(4-isobutyrylpiperazin-1-yl)propoxy)benzenesulfonamide; <74> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)propoxy)benzenesulfonamide; <75> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-hydroxypiperidin-1-yl)propoxy)benzenesulfonamide; <76> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)propoxy)benzenesulfonamide; <77> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-(methylamino)azetidin-1-yl)propoxy)benzenesulfonamide; <78> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-chloropiperidin-1-yl)propoxy)benzenesulfonamide; <79> N-(3-(5-chloro-1H-indol-3-yl)propyl)-6-(3-(piperazin-1-yl)propoxy)pyridine-3-sulfonamide; <80> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-fluoropiperidin-1-yl)propoxy)benzenesulfonamide; <81> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-(trifluoromethyl)piperidin-1-yl)propoxy)benzenesulfonamide; <82> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4,4-difluoropiperidin-1-yl)propoxy)benzenesulfonamide; <83> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methyl-1,4-diazepan-1-yl)propoxy)benzenesulfonamide; <84> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)propoxy)benzenesulfonamide; <86> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)naphthalene-1-sulfonamide; <87> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)propoxy)benzenesulfonamide; <88> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperidin-4-yl)propyl)amino)benzenesulfonamide; <90> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-1-yl)butyl)benzenesulfonamide; <91> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperazin-1-yl)butyl)benzenesulfonamide; <92> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(1-methylpiperidin-4-yl)propoxy)benzenesulfonamide; <93> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-4-yl)propoxy)benzenesulfonamide; <94> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-(3-(piperidin-4-yl)propoxy)benzenesulfonamide; <95> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-(3-(piperidin-1-yl)propoxy)benzenesulfonamide; <96> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <97> N-(3-(5-fluoro-1H-indol-3-yl)propyl)-4-(3-(piperidin-4-yl)propoxy)benzenesulfonamide; <98> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzenesulfonamide; <99> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(piperidin-4-yl)butyl)benzenesulfonamide; <100> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(pyrrolidin-1-yl)propoxy)benzenesulfonamide; <101> 4-(3-(azepan-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide; <102> 4-(3-(1,4-diazepan-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide; <103> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <104> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <105> N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluoro-4-(3-(4-hydroxypiperidin-1-yl)propoxy)benzenesulfonamide; <106> 4-(3-(1,4-diazepan-1-yl)propoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-3-fluorobenzenesulfonamide; <107> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <108> (R)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <109> (S)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <110> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-((3S,5R)-3,5-dimethylpiperazin-1-yl)propoxy)benzenesulfonamide; <111> (S)-N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3,4-dimethylpiperazin-1-yl)propoxy)benzenesulfonamide; <112> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(4-methylpiperazin-1-yl)butyl)benzenesulfonamide; <113> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperazin-1-yl)propyl)amino)benzenesulfonamide; <114> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperidin-1-yl)propyl)amino)benzenesulfonamide; <115> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(4-(1-methylpiperidin-4-yl)butyl)benzenesulfonamide; <116> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((1-((4-methylpiperazin-1-yl)methyl)cyclopropyl)methoxy)benzenesulfonamide; <117> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((1-(piperazin-1-ylmethyl)cyclopropyl)methoxy)benzenesulfonamide; <118> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)phenoxy)benzenesulfonamide; <119> 4-(3-Bromophenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide; <120> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperidin-1-yl)phenoxy)benzenesulfonamide; <121> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)phenoxy)benzenesulfonamide; <122> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methyl-1,4-diazepan-1-yl)phenoxy)benzenesulfonamide; <123> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-methylpiperazin-1-yl)phenyl)amino)benzenesulfonamide; <124> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(piperazin-1-yl)phenyl)amino)benzenesulfonamide; <125> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(4-methylpiperazin-1-yl)pyrimidin-2-yl)amino)benzenesulfonamide; <126> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-morpholinophenyl)amino)benzenesulfonamide; <127> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(piperazin-1-yl)pyrimidin-2-yl)amino)benzenesulfonamide; <128> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-morpholinophenoxy)benzenesulfonamide; <129> 4-(3-(1,4-diazepan-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide; <130> 4-(3,5-bis(4-methylpiperazin-1-yl)phenoxy)-N-(3-(5-chloro-1H-indol-3-yl)propyl)benzenesulfonamide; <131> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((6-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide; <132> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((6-(piperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide; <133> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide; <134> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(piperazin-1-yl)pyridin-2-yl)amino)benzenesulfonamide; <135> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(pyrrolidin-1-yl)phenoxy)benzenesulfonamide; <136> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-hydroxypiperidin-1-yl)phenoxy)benzenesulfonamide; <139> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((3-(4-hydroxypiperidin-1-yl)phenyl)amino)benzenesulfonamide; <142> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-((4-(4-methylpiperazin-1-yl)phenyl)amino)benzenesulfonamide; <146> N-(3-(5-chloro-1H-indol-3-yl)propyl)-2-((3-(piperazin-1-yl)propyl)amino)thiazole-5-sulfonamide; <150> N-(2-((5-chloro-1H-indol-3-yl)methyl)phenyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <151> N-(4-(5-chloro-1H-indol-3-yl)butan-2-yl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <152> N-(4-(5-chloro-1H-indol-3-yl)butan-2-yl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <153> N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <154> N-(3-(5-bromo-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <158> N-(2-(5-chloro-1H-indol-3-yl)ethyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <159> N-(2-(5-chloro-1H-indol-3-yl)ethyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <162> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methyl-3-oxopiperazin-1-yl)propoxy)benzenesulfonamide; <163> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(3-oxopiperazin-1-yl)propoxy)benzenesulfonamide; <164> N-(3-(5,7-dichloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <165> N-(3-(5,7-dichloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <167> N-(3-(5-chloro-1H-indazol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <168> N-(3-(5-chloro-1H-indazol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <169> N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <170> N-(3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <177> N-((6-chloro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <178> N-((6-chloro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <183> N-(3-(5,6-dichloro-1H-indol-3-yl)propyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <184> N-(3-(5,6-dichloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <186> N-(3-(5-chloro-1H-indol-3-yl)propyl)-4-(3-(4-methylpiperazin-1-yl)propyl)benzenesulfonamide; <187> N-((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(4-methylpiperazin-1-yl)propoxy)benzenesulfonamide; <188> N-((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-4-(3-(piperazin-1-yl)propoxy)benzenesulfonamide; <189> 4-(3-(4-methylpiperazin-1-yl)propoxy)-N-((2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)benzenesulfonamide; <190> 4-(3-(Piperazin-1-yl)propoxy)-N-((2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)benzenesulfonamide.
6. A method for preparing a compound represented by Formula 1, the method comprising the steps of preparing a compound represented by Formula 1 by reacting a compound represented by Formula 2 with a compound represented by Formula 3 as shown in the following Reaction Formula 1: [Reaction 1] In reaction formula 1, Ar, R 1 , R 2 , R 3 , L 1 , L 2 and Z is as defined in Formula 1 of claim 1, J 1 is sulfonyl chloride; and J 2 It is an amine group.
7. A pharmaceutical composition for preventing or treating cancer, inflammatory diseases or metabolic diseases, comprising as an active ingredient a compound represented by Formula 1 of claim 1, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition according to claim 7, wherein the compound inhibits peptidylprolyl cis-trans isomerase NIMA interacting protein 1.
9. The pharmaceutical composition according to claim 7, wherein the cancer is selected from at least one of the following: pseudomyxoma, intrahepatic bile duct carcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, biliary tract cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullary cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small intestine cancer, meningioma, esophageal cancer, glioma, renal cancer, kidney cancer. cancer), heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureter cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric stump cancer, gastrointestinal stromal cancer, Wilms cancer, breast cancer, sarcoma, penile cancer, pharyngeal cancer, chorionic villus disease of pregnancy, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectoid cancer, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer, and thymus cancer.
10. The pharmaceutical composition according to claim 7, wherein the inflammatory disease is selected from at least one of the following: arthritis, encephalomyelitis, meningitis, peritonitis, osteomyelitis, encephalitis, ankylosing spondylitis, vasculitis, uveitis, ileitis, atherosclerosis, myositis, leukocyte damage, inflammatory bowel disease, ulcerative colitis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, gout, vasculitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, nephritis, intraperitoneal disease, sepsis, systemic inflammatory response syndrome, myocardial infarction, allergic diseases, asthma, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, chronic obstructive pulmonary disease and periodontitis.
11. The pharmaceutical composition according to claim 7, wherein the metabolic disease is selected from at least one of the following: obesity, diabetes, hypertension, hyperlipidemia, hypercholesterolemia, arteriosclerosis, fatty liver, gout, stroke and heart disease.
12. Use of the compound represented by formula 1 according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof in the preparation of a medicament for preventing or treating cancer, inflammatory diseases or metabolic diseases.
13. The use according to claim 12, wherein the compound inhibits peptidylprolyl cis-trans isomerase NIMA interacting protein 1.
14. The method according to claim 12, wherein the cancer is selected from at least one of the following: pseudomyxoma, intrahepatic bile duct carcinoma, hepatoblastoma, liver cancer, thyroid cancer, colon cancer, testicular cancer, myelodysplastic syndrome, glioblastoma, oral cancer, lip cancer, mycosis fungoides, acute myeloid leukemia, acute lymphocytic leukemia, basal cell carcinoma, ovarian epithelial cancer, ovarian germ cell cancer, brain cancer, pituitary adenoma, multiple myeloma, gallbladder cancer, bile duct cancer, ovarian cancer, colorectal cancer, chronic myeloid leukemia, chronic lymphocytic leukemia, retinoblastoma, choroidal melanoma, ampullary cancer, bladder cancer, peritoneal cancer, parathyroid cancer, adrenal cancer, nasal cancer, non-small cell lung cancer, tongue cancer, astrocytoma, small cell lung cancer, pediatric brain cancer, pediatric lymphoma, pediatric leukemia, small intestinal cancer, meningioma, esophageal cancer, glioma, renal cancer, kidney cancer cancer), heart cancer, duodenal cancer, malignant soft tissue cancer, malignant bone cancer, malignant lymphoma, malignant mesothelioma, malignant melanoma, eye cancer, vulvar cancer, ureter cancer, urethral cancer, cancer of unknown primary site, gastric lymphoma, gastric cancer, gastric stump cancer, gastrointestinal stromal cancer, Wilms cancer, breast cancer, sarcoma, penile cancer, pharyngeal cancer, chorionic villus disease of pregnancy, cervical cancer, endometrial cancer, uterine sarcoma, prostate cancer, metastatic bone cancer, metastatic brain cancer, mediastinal cancer, rectal cancer, rectoid cancer, vaginal cancer, spinal cord cancer, vestibular schwannoma, pancreatic cancer, salivary gland cancer, Kaposi's sarcoma, Paget's disease, tonsil cancer, squamous cell carcinoma, lung adenocarcinoma, lung cancer, lung squamous cell carcinoma, skin cancer, anal cancer, rhabdomyosarcoma, laryngeal cancer, pleural cancer, blood cancer, and thymus cancer.
15. The use according to claim 12, wherein the inflammatory disease is selected from at least one of the following: arthritis, encephalomyelitis, meningitis, peritonitis, osteomyelitis, encephalitis, ankylosing spondylitis, vasculitis, uveitis, ileitis, atherosclerosis, myositis, leukocyte damage, inflammatory bowel disease, ulcerative colitis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, gout, vasculitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, nephritis, intraperitoneal disease, sepsis, systemic inflammatory response syndrome, myocardial infarction, allergic diseases, asthma, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, chronic obstructive pulmonary disease and periodontitis.
16. The use according to claim 12, wherein the metabolic disease is selected from at least one of the following: obesity, diabetes, hypertension, hyperlipidemia, hypercholesterolemia, arteriosclerosis, fatty liver, gout, stroke and heart disease.
Citation Information
Patent Citations
Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
WO2006089053A2
Benzenesulfonamide derivatives, preparation method thereof, and pharmaceutical composition for use in treating cancer and asthma
KR1020170110017A
1,3-Diheterocyclic metalloprotease inhibitors
US20030130271A1
Inhibitors of 15-lipoxygenase
US20060063823A1
1,3-diheterocyclic metalloprotease inhibitors
WO1998008822A1
